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1 Summary 
Neutrophils are key players of the innate immune system and are the most important 
effector cells of antibacterial defense. They carry an abundant pool of highly active 
neutrophil serine poteases that are mostly known for their destructive role during 
inflammation. In the past, much focus has been placed on proteinase 3 (PR3) and 
especially neutrophil elastase (NE) with regard to their destructive role during chronic 
inflammation. In recent years it has been shown that PR3 and NE are also regulators of 
inflammation and can influence the course of the inflammation. To deepen our 
understanding of the pro-inflammatory function of PR3 and NE, I analyzed their effects 
on chemokines in the first part of my thesis. I focused my work on one class of 
chemokines, the so-called ERL
+
 CXC chemokines, which attract neutrophils. Of 
particularl interest was MIP-2 as it is expressed in neutrophils. I was able to show that 
recombinant PR3 and NE can process the N-terminus of MIP-2. This trimming enhances 
the chemotactic activity of MIP-2. Extending the N-, but not the C-terminus abolished the 
chemotactic properties of MIP-2. As only active MIP-2 can trigger internalization of the 
corresponding receptor, CXCR2, I used FACS analysis to determine the CXCR2 binding 
properties of MIP-2. CXCR2 internalization was not observed on PR3/NE deficient 
PMNs when using N-terminally extended MIP-2. Only wild type PMNs were able to 
convert inactive MIP-2 into an active form and to trigger CXCR2 internalization. I 
concluded that MIP-2 is a substrate of PR3 and NE and processing of MIP-2 enhances 
recruitment of neutrophils.  
In the second part of my thesis, I focused on an alternative regulation of NE activity. I 
discovered that NE cleaves itself near the active site between A
188
 and G
189
, thereby 
changing its substrate specificity. To compare the two-chain form with intact NE, the 
exact active amount of each form was determined by titration. While the two-chain form 
of NE was much more slowly inhibited by α-1-protease inhibitor (α1PI), the most 
important inhibitor of elastase in the plasma, it retained its substrate specificity towards a 
certain subset of substrates. Deficiency of α1PI is associated with a higher risk of 
emphysema. In view of the pathogenicity of NE in several lung diseases, synthetic 
elastase inhibitors have been developed in pharmaceutical companies as potential 
therapeutic agents. I showed that one of the available small molecule inhibitors inhibited 
the two-chain form of NE only weakly. In conclusion, I detected a proteolytically 
modified form of NE that was able to escape inhibition by α1PI. This has been so far 
overlooked and was not considered during drug development. My studies provided strong 
evidence that the two-chain form of NE retains its pathogenicity. 
Zusammenfassung 
- 2 - 
 
Zusammenfassung  
Neutrophile Granulozyten sind ein wesentlicher Bestandteil des angeborenen 
Immunsystems und sind die wichtigsten Effektorzellen für die bakterielle Abwehr. Sie 
führen große Mengen an hochaktiven Neutrophilen-Serinproteasen mit sich. Letztere sind 
besonders wegen ihrer destruktiven Rolle bei Entzündungsprozessen bekannt und 
bedeutsam geworden. Der Schwerpunkt in der Erforschung von Proteinase 3 (PR3) und 
Neutrophilen-Elastase (NE) war bisher auf ihre pathogene und destruktive Funktion bei 
chronischen Entzündungen gerichtet. Erst in den letzten Jahren wurde jedoch deutlich, 
dass PR3 und NE Entzündungsprozesse steuern und somit Entzündungsverläufe 
beeinflussen können. Um die entzündungsförderlichen Effekte von PR3 und NE zu 
charakterisieren, habe ich die Wirkung von PR3 und NE auf Chemokine untersucht. In 
meiner Arbeit habe ich mich vor allem auf die sogenannten ELR
+
 CXC-Chemokine 
konzentriert, welche hauptsächlich Neutrophile anlocken. Mein Interesse galt vor allem 
MIP-2, da dieses auch von Neutrophilen produziert wird. Ich wies nach, dass PR3 und 
NE gezielt das N-terminale Ende von MIP-2 prozessieren. Die Verkürzung des 
N-Terminus von MIP-2 erhöht die chemotaktische Aktivität von MIP-2. Die 
Verlängerung des N-, nicht aber die des C-Terminus, hebt die chemotaktischen 
Eigenschaften von MIP-2 auf. Da der entsprechende Rezeptor, CXCR2 genannt, nur nach 
Stimulierung mit aktivem MIP-2 internalisiert wird, habe ich die Bindung von MIP-2 an 
CXCR2 mittels Durchflusszytometrie bestimmt. Eine CXCR2-Internalisierung fand in 
Granulozyten mit PR3/NE-Defizienz nicht statt, wenn N-terminal verlängertes MIP-2 
verwendet wurde. Nur Wildtypzellen konnten inaktives MIP-2 in aktives MIP-2 
umwandeln und damit die CXCR2-Internalisierung auslösen. Ich schlussfolgerte daraus, 
dass MIP-2 von PR3 und NE prozessiert wird und dies die Rekrutierung der Neutrophilen 
beschleunigt. 
Im zweiten Teil meiner Arbeit, untersuchte ich eine alternative Regulierung der NE-
Aktivität. Ich entdeckte, dass NE sich in der Nähe des aktiven Zentrums zwischen A
188
 
und G
189
 selbst schneidet und dadurch seine Substratspezifität verändert. Um die intakte 
und die zweikettige NE-Form zu vergleichen, wurde die exakte Menge an aktiver NE für 
beiden Formen mittels Titration ermittelt. Obwohl zweikettige NE viel langsamer von 
α-1-Protease Inhibitor (α1PI), dem wichtigsten Elastaseinhibitor im Plasma, inhibiert 
wird, behält die zweikettige NE ihre Substratspezifität für eine Subgruppe von Substraten 
bei. Eingeschränkte Inhibition durch α1PI erhöht bekanntermaßen das Risiko für 
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Emphysem. Aufgrund der pathogenen Rolle von NE bei Lungenkrankheiten und anderen 
chronisch-entzündlichen Erkrankungen wurden synthetische Elastaseinhibitoren von 
vielen pharmazeutischen Firmen entwickelt. Ich konnte zeigen, dass ein 
niedermolekularer Elastase-Inhibitor, ein bereits in klinischen Studien verwendeter 
Wirkstoffkandidat, den uns AstraZeneca zur Verfügung stellte, die zweikettige NE-Form 
nur sehr schlecht inhibiert. Ich konnte schließlich eine proteolytisch modifizierte Form 
der NE nachweisen, die sich der Inhibierung durch α1PI partiell entzieht. Diese Form 
wurde bisher übersehen und daher nicht bei der Medikamenten-Entwicklung 
berücksichtigt. Viele Hinweise in meinen Studien weisen darauf hin, dass NE nach 
autoproteolytischer Modifikation ihre Pathogenität beibehält. 
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2 Introduction  
2.1 Neutrophil granulocytes 
Our body has developed a fine tuned immune system to fight microorganisms that are 
able to cross the physical barriers of our body such as the skin. The first line of defense is 
formed by leukocytes of the innate immune defense system with neutrophils as the key 
players. A distinctive feature of granulocytes is the lobulated nucleus, which earned them 
the name polymorphonuclear cells (PMNs). Neutrophils are the most dominant subclass 
of PMNs. They make up 40-70% of all peripheral blood leukocytes, while eosinophil and 
basophil granulocytes only constitute less than 5% of leukocytes. The importance of 
PMNs can be seen in patients with neutropenia, who show an increased risk of infections 
with PMN counts considerably reduced and below 1500 per µl. Patients with neutrophils 
below 500 per µl have a severe risk of serious infections (Janeway et al., 2005; Metcalf, 
1991). 
Neutrophils are the first cells to arrive at an inflammatory site after residential 
macrophages are alerted to local danger signals. They form the majority of leukocytes 
within the first hours of inflammation before they are followed by blood derived 
macrophages (Janeway et al., 2005; Lawrence et al., 2002). Once arrived at the 
inflammatory site, they release the contents of their granules and start with the destruction 
of invading microorganisms. These granules are densely packed stores filled with 
proteins like myeloperoxidase, defensins, antibacterial peptides and proteases that enable 
the PMNs to react fast to immediate dangers (Borregaard et al., 2007). There are three 
different kinds of granules, primary (azurophilic), secondary (specific) and tertiary 
(gelatinase) granules. They are formed during different stages of granulocyte 
development and thus differ in their contents (Borregaard, 2010). PMNs internalize 
pathogens via phagocytosis, where phagosomes fuse with lysosomes to so called 
phagolysosomes (Janeway et al., 2005). The neutral pH of phagolysosomes activates 
neutral proteases like the neutrophil serine proteases (NSPs), which are kept inactive by 
the low pH and binding to proteoglycans in the primary granules. During the so called  
respiratory burst PMNs produce reactive oxygen species (ROS) which together with other 
antimicrobial proteins from the lysosomes, kill the engulfed bacteria (Dale et al., 2008; 
Janeway et al., 2005). Although killing microorganisms is an important function, it is not 
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the only function of PMNs. PMNs are also involved in wound healing and regulation of 
the immune response during inflammation (Appelberg, 2007; Nathan, 2006).  
2.2 Neutrophil serine proteases 
Neutrophil serine proteases (NSPs) are a family of structurally related proteases that 
consists of four active members: neutrophil elastase (NE), cathepsin G (CG), proteinase 3 
Fig 2.1: Mechanism of serine protease catalysis. (A) features the initial state of active center. The 
hydroxyl group of Ser
195
 is polarized to a highly nucleophilic state with the help of Asp
102
 and His
57
 
and attacks the main chain of the substrate. The resulting tetrahedal intermediate is kept stable by the 
oxyanion hole (grey circle) and His
57
. The tetrahedal intermediate is split into the acyl-enzyme 
complex (B) and the amino group of the C-terminal fragment after receiving a proton from His
57
. The 
acyl-enzyme complex is attacked by the catalytic water resulting in a different tetrahedal intermediate 
that is again stabilized by the oxyanion hole and a protonated H
57
. In (C) the carboxylic acid product 
is released and the original state of the active center is restored. 
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(PR3), and neutrophil serine protease 4 (NSP4) (Perera et al., 2012; Pham, 2006). They 
are chymotrypsin-like serine proteases, whose active center features the catalytic triad 
His
57
, Asp
102
 and Ser
195
.  
 The reaction can be divided into two steps, the acylation and deacylation step (Fig 2.1) 
(Berg et al., 2003; Hedstrom, 2002). The carboxylate group of Asp
102
 forms a hydrogen 
bond with the imidazole ring from His
57
, which in turn forms a hydrogen bond with 
Ser
195
. Because of these interactions the oxygen of Ser
195
 becomes strongly nucleophilic. 
During the acylation reaction the hydroxyl group of Ser
195
 attacks the main chain of the 
substrate and forms a tetrahedal intermediate (not shown), which is stabilized by the 
oxyanion hole. Once the amine group receives a proton from the His
57
 the tetrahedal 
intermediate collapses into the acyl-enzyme complex and the C-terminal part of the 
substrate and  (Berg et al., 2003; Hedstrom, 2002). During the deacylation step a water 
molecule attacks the acyl-enzyme complex and protonates His
57
. The resulting tetrahedal 
complex (not shown) is kept stable by the oxyanion hole before it splits into a carboxylic 
acid product and the restored catalytic triad (Berg et al., 2003; Hedstrom, 2002). 
 
A large proportion of the NSPs are active in the phagolysosome, where they degrade 
ingested microorganisms. Their microbicidal ability is crucial for the defense against 
bacteria and fungi (Belaaouaj et al., 2000; de Haar et al., 2006) (Reeves et al., 2002). 
NSPs are also known to degrade the extracellular matrix (ECM) which is useful for 
extravasation, but uncontrolled excessive activity can also lead to serious tissue damage 
(Chua and Laurent, 2006; Pham, 2006). Besides their destructive role, emerging evidence 
indicates that NSPs can also regulate the inflammatory process (Kessenbrock et al., 2011; 
Pham, 2006). 
2.2.1 Regulatory functions of NSPs 
The small fraction of NSPs that is released into the extracellular space upon activation is 
thought to have a regulatory function. Externalized NSPs are bound to the membrane and 
to neutrophil extracellular traps (NETs) (Brinkmann et al., 2004; Campbell et al., 2000; 
Kessenbrock et al., 2009; Owen et al., 1995) Another factor contributing to a prolonged 
activity, is the local level of active inhibitors. These can be inactivated through oxidation 
or proteolysis (Liu et al., 2000; Owen and Campbell, 1999). NSPs are probably involved 
in immune complex (IC)-mediated inflammation, since IC-mediated inflammation is 
impaired in NSP-deficient mice (Kessenbrock et al., 2008; Raptis et al., 2005). 
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Recently, it was shown that the anti-inflammatory protein progranulin is degraded by NE 
and PR3 (Kessenbrock et al., 2008). Progranulin inhibits tumor necrosis factor α 
(TNF-α)-induced immune responses, thereby reducing the respiratory burst and 
degranulation (Zhu et al., 2002). Lack of PR3 and NE leads to an accumulation of 
progranulin resulting in decreased inflammation (Kessenbrock et al., 2008). 
Pham et al. showed that CG indirectly enhanced integrin clustering by an as yet unknown 
mechanism. Consequence of this effect is the reduced secretion of macrophage 
inflammatory protein 2 (MIP-2) from neutrophils. MIP-2 belongs to the family of 
chemokines and is crucial for recruiting PMNs. Indirect regulation of chemokine levels 
are probably not the only way NSPs can modify chemokine activity. 
2.2.2 Pathophysiological functions of NSPs 
Despite the important role of NSPs in immune defense, a tight regulation of their activity 
is necessary, as an imbalance between proteases and inhibitors often leads to disease. 
NSPs are especially involved in chronic inflammatory diseases like emphysema and 
chronic inflammatory lung diseases, which will be discussed in detail later (Roghanian 
and Sallenave, 2008b). The following diseases are examples that emphasize the need to 
control the timing, localization and intensity of NSP activity. In addition, NSPs also play 
an important role in granulomatosis with polyangiitis, an autoimmune disease, 
independent of their activity (Korkmaz et al., 2010). 
2.2.2.1 Hereditary neutropenias 
One example that demonstrates the importance of timing and sorting of NSPs can be seen 
in cyclic and severe congenital neutropenia. This disease is often associated with 
mutations of ELANE, the gene encoding NE, resulting in a misplacement of NE (Dale et 
al., 2002; Klein, 2009). The function of NE in pathogenesis is not known yet. However, 
several observations indicate that mislocalization and/or misfolding of NE is one 
important factor that either induces apoptosis or inhibits differentiation of myeloblasts 
into neutrophils (Horwitz et al., 2007). 
2.2.2.2 Papillon-Lefevre-syndrome 
The activity of NSPs needs to be tightly controlled. Too high or too little activity can 
result in disease, as can be seen in patients suffering from Papillon-Lefèvre syndrome 
(PLS). In these patients the dipeptidyl peptidase I (DPPI) is missing (Dalgıc et al., 2011), 
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which is essential for the activation of NSPs. Because DPPI is missing, NSPs stay in their 
pro-protease or zymogen form, thus PLS patients have no active NSPs. In fact, even the 
protein level of zymogen NSPs is reduced (de Haar et al., 2004, 2006). These patients 
often have severe periodontal disease (periodontitis) as well as palmoplanter 
hyperkeratosis, thickened skin on palms and soles (Dalgıc et al., 2011).   
2.2.2.3 Granulomatosis with polyangiitis 
Granulomatosis with polyangiitis (GPA) is an autoimmune disease defined by the 
presence of antineutrophil cytoplasmic autoantibodies (ANCA) and necrotizing vasculitis 
(Korkmaz et al., 2010). These antibody recognize mainly PR3 (Kallenberg et al., 2006). 
Although inflammation can take place in every organ, the upper and lower respiratory 
tract as well as the kidneys are the most affected (Korkmaz et al., 2010).  
2.2.3 Chemokines as substrates of NSPs 
Chemokines are a family of chemoattractant cytokines that bind to G protein-coupled 
receptors expressed on leukocytes (Janeway et al., 2005). The conserved N-terminal 
cysteines of chemokines are used to divide the chemokines into four classes: CXC, CC, 
XC and CX3C (Baggiolini, 2001). The C stands for cysteine and the X for any amino 
acid residue. The receptors were named according to which chemokine class they bind. 
The CXC class is further subdivided into chemokines that feature an ELR motif before 
the CXC motif or not (Baggiolini, 2001). In this study we focus on CXC chemokines 
containing the ELR motif (ELR
+
-CXC chemokines), because they bind to the CXCR2 
receptor, which is expressed on neutrophils (Baggiolini, 2001; Janeway et al., 2005). 
2.2.3.1 Interleukin-8 
The most important and best studied ELR
+
CXC chemokine in humans is CXCL8, also 
known as interleukin-8 (IL-8). Interestingly IL-8 is also expressed by neutrophils at 
relatively high levels (Scapini et al., 2000). Various naturally occurring IL-8 isoforms 
have been identified with different posttranslational modifications (Mortier et al., 2008; 
Proost et al., 2008). One example is the citrullination of Arg5. It does not change the 
chemotactic and angiogenic properties of IL-8 in vitro, but improves the stability of IL-8 
in vivo (Proost et al., 2008). The most common modification of IL-8 is the trimming of 
the N-terminus (Mortier et al., 2008; Wolf et al., 2008). The amino-terminal domain with 
its ELR motif is essential for receptor activation (Clark-Lewis et al., 1991), thus changing 
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its length influences the chemotactic activity of IL-8. Several proteases in vitro are able to 
process IL-8 that can either enhance or inactivate IL-8 activity (Fig 2.2) (Mortier et al., 
2008; Wolf et al., 2008). For example matrix metalloproteinase 12 (MMP-12) inactivates 
IL-8 by destroying the ELR motif (Dean et al., 2008). In contrast, cleavage of IL-8 after  
Ala
7
 by PR3 converts IL-8 to a more chemotactic form  (Nourshargh et al., 1992; 
Padrines et al., 1994).  
2.2.3.2 Murine CXC ELR+  
While there are seven human ELR+-CXC chemokines, only four were found in mice: 
MIP-2, LIX, KC, DCIP-1. None of these are true homologues of IL-8, but like IL-8 
macrophage inflammatory protein (MIP-2 or CXCL2) is very abundantly expressed in 
neutrophils and can therefore be regarded as the appropriate murine equivalent of IL-8 
(Pham, 2006).  Very little is known how chemokine processing occurs in vivo. 
2.3 Neutrophil Elastase 
Neutrophil elastase, named for its ability to degrade elastin, is abundantly expressed in 
neutrophils. The high NE concentration of over 5 mM in azurophilic granules suggests an 
important role for elastase (Liou and Campbell, 1995). As already mentioned NE 
influences inflammation by processing and degrading inflammatory regulators 
(Kessenbrock et al., 2008; Pham, 2006). It has also been reported that the clearance of 
gram-negative bacteria is impaired in NE knockout mice (Belaaouaj et al., 1998). 
Internalized bacteria were not killed and could escape from the  phagolysosome 
(Belaaouaj et al., 1998). Despite its importance in antimicrobial defense, NE has been 
Fig 2.2: Naturally occurring modifications of IL-8 at the N-terminus. This figure shows 
the N-terminal sequence of IL-8 from Ala
1
 to Thr
17
. MMP-12 cleaves within the ELR motif 
of IL-8, thereby inactivating it. Trimming of the N-terminus by MMP-8, MMP-9 and PR3 
enhances chemotactic activity of IL-8. Citrullination of IL-8 has no influence on chemotactic 
activity, but enhances stability of IL-8 in vivo. 
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studied much more, because of its pathogenic role in inflammation. Due to its ability to 
degrade elastin and other components of the ECM, NE is often closely connected to tissue 
destruction in chronic inflammatory diseases (Barroso et al., 2006; Chua and Laurent, 
2006; Heinz et al., 2012; Henriksen and Sallenave, 2008; Roghanian and Sallenave, 
2008a).  
2.3.1 NE in lung diseases  
Unopposed NE activity is highly destructive and can lead to disease. Especially in 
chronic inflammatory lung diseases, where high NE activity between 0.5 to 5 µM in the 
airways can be detected, NE aggrevates the disease  (Döring et al., 1995). In the 
following the two most relevant lung diseases concerning NE will be introduced. 
2.3.1.1 Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease is a compendium of lung diseases that all show an 
irreversible airflow reduction, with chronic bronchitis and emphysema as the most 
prominent symptoms (Barnes et al., 2003). Since injection of human NE (hNE) into the 
lung results in emphysema, excess NE activity is regarded as one major risk factor for 
emphysema development (Barnes et al., 2003; Fujita et al., 1990; Senior et al., 1977). 
Adding to this line of reasoning, patients lacking the most important NE inhibitor alpha-
1-protease inhibitor (α1PI) often develop emphysema (Fujita et al., 1990; Roghanian and 
Sallenave, 2008b). Degradation of ECM, promotion of proinflammatory proteins and 
stimulation of mucin production are the most important pathogenic features of NE during 
COPD (Roghanian and Sallenave, 2008b). 
2.3.1.2 Cystic fibrosis 
Cystic fibrosis is a hereditary recessive disease. Mutation of the gene encoding the cystic 
fibrosis transmembrane conductance regulator results in thickening of the mucus as well 
as severe and chronic inflammation of the lung with massive neutrophil infiltration (Kelly 
et al., 2008; Voynow et al., 2008). High levels of NSPs are reported to increase mucus 
secretion (Voynow et al., 2008). Additionally, high NE activity leads to epithelial 
disruption and prolongs inflammation (Kelly et al., 2008; Roghanian and Sallenave, 
2008b; Voynow et al., 2008). Similar to COPD, disruption of the protease-antiprotease 
balance in favor for the protease gives rise to disease (Kelly et al., 2008; Voynow et al., 
2008). 
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2.3.2 Regulation of NE activity 
The previous chapters showed how important it is to keep a tight grip on the activity of 
NSPs. While the activity of other proteins can be controlled by up- or down-regulation of 
the expression of those protein, NSPs are only expressed during neutrophil development 
in the bone marrow and stored in azurophilic granules (Pham, 2006). Therefore other 
mechanisms e.g. the lowering of the pH, biosynthesis of zymogen precursors and 
inhibitors are used to maintain control over NSP activities. 
2.3.2.1 pH  
As NSPs are toxic to the neutrophil, they are kept inactive in the azurophilic granules 
through a low pH. During the catalysis His
57
 acts as a base and accepts the proton of 
Ser
195
 (Fig2.1) (Hedstrom, 2002).  At a low pH His
57
 (pKa = 6.08) is protonated and thus 
is unable to act as a base any longer. Furthermore, NSPs are bound to proteoglycans 
(Pham, 2008). The presence of superoxide anion triggers the K
+
-flux into the  
phagolysosome (Reeves et al., 2002). The K
+
-influx increases the osmolarity and 
solubilizes the NSPs in the phagolysosome. The oxygen radicals neutralize the pH, 
thereby activating the NSPs (Reeves et al., 2002). 
2.3.2.2 Proteolysis 
It is a common principle of nature to regulate protease activity by other proteases. The 
most prominent examples are the clotting cascade and the complement system, where the 
components of these cascades are available in their zymogen form (Janeway et al., 2005). 
Each protease activates a zymogen, which in turn activates another zymogen (Janeway et 
al., 2005). Some proteases can even activate themselves by autoprocessing as can be seen 
with MMP-9 and trypsin (Brodrick et al., 1978; Kay and Kassell, 1971; Makowski and 
Ramsby, 2005). 
2.3.2.2.1 Processing by other proteases 
In general, proteases are expressed as zymogens and are activated by the removal of the 
propeptide with the help of another protease. As already mentioned, the protease 
responsible for converting Pro-NSPs into mature NSPs is DPPI (Pham, 2008). DPPI 
removes a two amino acid long peptide, thereby freeing the N-terminus Ile
16
-Val
17
 
(Hedstrom, 2002; Pham, 2006). The liberated Ile
16
 builds a salt bridge with the Asp
194
, 
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inducing a conformational change in the protease, which results in the formation of the 
oxyanion hole as well as the S1 site pocket  (Hedstrom, 2002).  
2.3.2.2.2 Self-cleavage 
There are actually several examples for self-activating proteases. Self-activation is 
probably an enhancing mechanism to accelerate conversion of the zymogen. Besides 
self-activation, self-cleavage also can lead to inactivation or change of specificity. 
Trypsin is a very good example for different modalities of influencing the activity of a 
protease by self-cleavage.  
 Trypsin belongs to the family of serine proteases and is active as a digestive enzyme at 
neutral pH in the duodenum (Chen et al., 2001; Hedstrom, 2002). Trypsinogen, the 
zymogen of trypsin, is expressed in the pancreas and then secreted to the duodenum, 
where enterokinase starts its conversion to trypsin (Chen et al., 2001; Rinderknecht, 
1986). Active trypsin then in turn activates other digestive proteases (Rinderknecht, 
1986). 
Interestingly, enterokinase only initiates trypsin activation. The newly formed, active 
trypsin actually converts trypsinogen to trypsin (Brodrick et al., 1978; Chen et al., 2001; 
Kay and Kassell, 1971). This reaction is largely dependent on pH and Ca
2+
-concentration 
(Brodrick et al., 1978; Kay and Kassell, 1971; McDonald and Kunitz, 1941). As 
previously described for NSPs, cleavage of the Lys
15
/Ile
16
 bond enables Ile
16
 to interact 
with Asp
194
 (Bode, 1979; Bode et al., 1978).  
Although trypsin is active in the duodenum, deregulated trypsin activity actually leads to 
pancreatitis (Chen et al., 2001; Whitcomb et al., 1996). Premature activation of trypsin in 
the pancreas instead of the duodenum triggers the disease (Chen et al., 2001). Whitcomb 
et al. were the first to report that mutation of the Arg
122
 in the cationic trypsinogen causes 
pancreatitis. The mutation eliminates an internal autolysis site, through which trypsin can 
inactivate itself. Since then, many other mutations have been reported that all have the 
same effect of eliminating the autolysis site (Chen et al., 2001). Removal of this self-
regulating mechanism of trypsin can lead to pancreatitis. This finding once again 
underlines the importance of self-cleavage as a regulatory mechanism. 
It has been reported that trypsin features an additional self-cleavage site between 
Lys
188
/Asp
189
 (Smith and Shaw, 1969). Cleavage of this bond changes the specificity of 
trypsin to a chymotrypsin-like specificity (Keil-Dlouhá et al., 1971). The S1 pocket is 
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formed by the residues 189—192, 214-216 and 224-228 (Hedstrom, 2002). The residue 
Asp
189
 is very important for the Arg and Lys specificity of trypsin and lies at the bottom 
of the S1 pocket (Hedstrom, 2002). Cleavage between Lys
188
 and Asp
189
 changes the 
conformation of the S1 pocket which leads to the chymotrypsin-like specificity. Although 
the biological function of this cleavage has not been elucidated yet, its existence is 
important for trypsin production. Commercially available trypsin is methylated to avoid 
this particular self-cleavage and treated with tosyl phenylalanyl chloromethyl ketone 
(TPCK) to suppress chymotrypsin-like activity from already nicked trypsin. 
2.3.2.3 Inhibition with serpins 
Normally, large amounts of inhibitors are expressed to keep protease activity under 
control. For serine proteases the most important inhibitors are the serpins. As the name 
indicates most members of the serpin superfamily are serine protease inhibitors, although 
this family also includes non-inhibitory members like ovalbumin. There are 36 members 
known in humans that are involved in inflammation, coagulation and fibrinolysis 
(Huntington, 2011).  
Serpins have three β–sheets, 8-9 α-helixes and a reactive center loop (RCL) (Gettins, 
2002). In its native conformation the 20-24 residue long RCL is a flexible loop that lies 
outside of the main structure and therefore is freely accessible by the protease 
(Huntington, 2011). Curiously, the native conformation of the serpins is not the most 
stable conformation. In its active state, the β–sheet A consists of five strands (Gettins, 
2002; Gooptu and Lomas, 2009). The serpins switch to a hyperstable conformation by 
inserting the RCL into the β–sheet A, which turns the β–sheet A into a complete 
antiparallel β–sheet (Gettins, 2002; Gooptu and Lomas, 2009).  
Covalent inhibition of proteases by serpins occurs in two consecutive steps. First, the 
protease is reversibly inhibited by the formation of a Michaelis complex (Gettins, 2002; 
Gooptu and Lomas, 2009). In the second step an ester bond is formed between the 
protease and serpin, resulting in an irreversible inhibition (Gettins, 2002; Gooptu and 
Lomas, 2009). Incorporation of the RCL into the β–sheet A is favored upon cleavage of 
the RCL by the protease (Gettins, 2002; Gooptu and Lomas, 2009). The classical 
orientation of serpins features the RCL on top of the serpin, so in a canonical complex the 
protease sits above the serpin (Huntington, 2011). After the acyl-enzyme complex is 
formed, the RCL inserts into the β–sheet A and the protease is relocated to the bottom of 
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the serpin (Gettins, 2002; Huntington, 2011). The structural change distorts the active 
center of the protease and destroys the oxyanion hole (Gettins, 2002; Huntington, 2011). 
That is why the deacylation cannot occur and the protease is trapped with a covalent bond 
to serpin. If the deacylation is faster than the rearrangement of the serpin, the serpin will 
merely serve as a substrate and the protease will not be inhibited (Gettins, 2002). 
2.3.2.3.1 α-1 protease inhibitor (α1PI) 
A very important member of serpins is the plasma protein α-1 protease inhibitor (α1PI). 
Plasma protease inhibitors make up 10 % of all plasma proteins (Travis et al., 1988). Out 
of these inhibitors, α-1-protease inhibitor (α1PI) with a concentration of 20 -53 µM is the 
most abundant one in plasma (Hortin et al., 2008; Stoller and Aboussouan, 2012; Travis 
et al., 1988). While it has been first recognized for its ability to inhibit pancreatic trypsin 
and has thus been called α-1-anitrypsin formerly, α1PI is the best and most efficient 
inhibitor for NE (Travis and Salvesen, 1983). As an acute phase protein α1PI levels are 
increased during inflammation (Travis et al., 1988). 
Lack of α1PI is associated with emphysema and patients suffering from α1PI deficiency 
are currently treated with intravenous application of α1PI (Gooptu et al., 2009). Several 
mutations have been found to cause α1PI deficiency. In Europe the most common 
mutation is the so called Z variant of α1PI (Z α1PI), where Glu
342
 is changed to Lys 
(Carrell et al., 1994; Gooptu et al., 2009). Glu
342
 is located at the hinge region between 
the β-sheet and the RCL and promotes α1PI polymerization (Carrell et al., 1994; Gooptu 
et al., 2009; Hopkins et al., 1993). α1PI plasma levels of individuals that are homozygous 
for Z α1PI have only 10 -15 % of a normal level (Carrell et al., 1994; Gooptu et al., 
2009). Additionally, patients carrying the Z α1PI also often have liver diseases, because 
hepatocytes are the main producers of α1PI. Due to its tendency to polymerize, Z α1PI is 
retained in inclusion bodies and damages the hepatocytes by accumulation (Gooptu et al., 
2009). 
2.3.2.3.2 MNEI 
Monocyte neutrophil elastase inhibitor (MNEI), also known as SERPINB1, belongs to the 
clade of OV-serpins (Benarafa et al., 2002). OV-serpins lack a secretory signalpeptide 
and are primarily active in the cytoplasm (Benarafa et al., 2002). MNEI is very efficient 
against all three NSPs, but its activity against CG seems especially essential for 
neutrophil survival (Cooley et al., 2001; Zhou et al., 2001). 
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3 Material and methods 
3.1 Nucleic acid methods 
3.1.1 Polymerase-chain reaction (PCR) 
Using a heat resistant DNA polymerase, a defined DNA fragment can be easily 
multiplied. The PCR was used to obtain sufficient amount of DNA necessary for further 
cloning steps. A typical PCR cycle consists of a denaturation, annealing and elongation 
step. The conditions used are described in the tables below. The Phusion High-Fidelity 
DNA polymerase from Finnzymes (New England Biolabs) was used for the PCR. 
PCR-mix 
400 nM primer 1 
400 nM primer 2 
5-10 ng template: plasmid 
200 µM dNTPs 
1 x HF-buffer (Finnzymes) 
1.25 U DNA polymerase 
PCR program 
 temperature time   
initial denaturation 94°C 30 sec  
denaturation 94°C 15 sec  
annealing dependent on primers 1 min 25 cycles 
elongation 72°C 1 min/kb of product   
final elongation 72°C 10 min  
3.1.2 Restriction digest 
For each digest we used a 3-5 times excess of enzyme (3-5 units/ µg DNA) with the 
recommended buffer and temperature. In general 1-5 µg DNA was digested. All enzymes 
besides AbsI (Novosibirsk, Russia), were pursued from New England Biolabs. To remove 
the enzymes and undigested vector, the cleaved products were run on a 1% agarose gel 
(see below) and QIAquick gel extraction kit (QIAGEN) was used to purify the DNA from 
the gel. 
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3.1.3 DNA gel electrophoresis 
Running DNA fragments on agarose gels in an electrical field separates the DNA 
fragments by size. To the 1% agarose gels (w/v) 1 µg/ml ethidium bromide was added to 
visualize the DNA. The agarose gels were prepared with TAE buffer, which was also 
used as a running buffer for the gels. To identify the size of the fragments the Gene Ruler 
1 kb marker (Ferments, Thermo Fisher Scientific) was used. 
50 x TAE 
 
 
 
10 x sample buffer 
0.25% bromphenol blue 
0.25% xylene cyanol 
50% glycerol 
3.1.4 Dephosphorylation 
The digested vector is dephosphorylated to prevent the religation of the vector. Only the 
phosphorylated fragment can then close the plasmid again. For the dephosphorylation 
alkaline phosphatase (New England Biolabs) was used according to the manufacturer’s 
instruction. 
3.1.5 Ligation 
Ligase joins together the 3’hydroxyl and 5’phosphate end of DNA fragments, resulting in 
a covalent diphosphoester bond. A phosphorylated 5’end and adenosine triphosphate 
(ATP) are necessary for this reaction.   
During a common reaction  50 ng vector, 5 times molar excess of fragment and 1 µl T4 
DNA ligase are incubated in 50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM 
dithiothreitol, pH 7.5 for two hours at room temperature. 
 
3.1.6 Transformation 
For each ligation reaction 100 µl competent bacteria were thawn on ice. After adding the 
DNA (5 µl ligation preparation or 10 ng plasmid DNA) the bacteria were incubated on ice 
242 g Tris 
57.1 ml acetic acid 
100 ml 0.5M EDTA, pH 8.8 
 Fill up to 1 L with H20 
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for 20 min, followed by a heat shock at 42°C for 1 min. The sample was shortly cooled 
on ice again before 1 ml of Luria-Bertani (LB) medium was added. The bacteria were 
incubated to recover at 37°C for one hour. For the selection 100 µl of the suspension were 
plated on agar plates with antibiotics (ampicillin 100 µg/ml) and incubated at 37°C 
overnight. 
LB-medium 
1% tryptone 
0.5% yeast extract 
1% NaCl 
1.5% agar (only for plates) 
3.1.7 Competent cells 
A single colony of the E. coli strain DH5α is grown in 50 ml LB medium at 37°C over 
night. With 4 ml of this culture a new 200 ml culture is set up. Upon reaching an OD590 of 
0,375-0.6 the bacteria are cooled on ice for ten minutes in precooled 15 ml falcons. After 
centrifuging the cells at 4°C and 3000 rpm for 7 min, the pellet is resuspended in 10 ml 
ice cold CaCl2 solution. This step is repeated to ensure the complete removal of media. 
After 30 min of incubation on ice, the bacteria are centrifugated and are resuspended in 
2 ml ice cold CaCl2 solution. Aliquots (100 µl) of the cells are shock frozen using a mix 
of dry ice and isopropanol. The competent cells are stored at -80°C. It is crucial to 
precool all buffers and centrifuges for the whole procedure. 
CaCl2-Lösung 
60 mM CaCl2 
15% glycerol 
10 mM  PIPES, pH 7 
3.1.8 DNA purification 
Transformed bacteria are stored as glycerol stocks (17.5% glycerol) at -80°C after 
verification. For DNA isolation an overnight culture (minipreps: 2-5 ml, maxipreps: 200 
ml) is needed. The DNA is then isolated using the QIAprep Spin Miniprep Kit 
(QIAGEN) or Plasmid Maxi Prep (QIAGEN) or PureYield™ Plasmid Maxiprep System 
(Promega) respectively according to the manufacturer’s instruction. 
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3.2 Protein methods 
3.2.1 Antibody list 
antigen species dilution manufacturer Cat. No. 
murine MIP-2 rabbit 1:5000 Preprotech 500-P130 
Human NE rabbit 1:1000 Abcam ab68672 
Human NE mouse For IP QED 13203 
His-tag, 3D5 mouse 1:2500 E. Kremmer - 
human haptoglobin rabbit 1:1000 Dako A0030 
Gr-1/ Ly-6G (mouse) rat 1:200 BD Pharmingen 553126 
CXCR2, 242216 rat 1:200 R&D Systems MAB2164 
IgG, FITC
† 
rat 1:200 BD Pharmingen 553988 
murine IgG+IgM, HRP* goat 1:2500 Pierce 31444 
rabbit IgG, HRP* goat 1:5000 Jackson ImmunoResearch 111-035-006 
†Fluorescein isothiocyanate (FITC), * horseradish peroxidase (HRP) 
3.2.2 Affinity chromatography 
All recombinant proteins were expressed with a C-terminal his-tag, which binds to Ni
2+
 
ions. The proteins were purified using nickel columns that mainly differ in their matrix 
material and have varying binding capacities. The protein is eluted with imidazole, which 
competes with the protein for the nickel binding sites.  
3.2.2.1 HisTrap™ HP Columns (GE Healthcare)  
The matrix of these columns is sepharose and these columns are compatible with 
ÄktaPrime Plus (GE Healthcare) that was used for the purification. Before loading, the 
supernatant was dialyzed against the washing buffer (20 mM Tris-HCl pH7.4, 300 mM 
NaCl). A continuous imidazole gradient was applied to elute bound proteins. For this 
washing buffer and elution buffer (20 mM Tris-HCl pH7.4, 300 mM NaCl, 1M 
imidazole) were mixed continuously. The maximum capacity of a column is 40 mg, of 
His-tagged proteins. These columns were to purify 250-600 ml supernatant of mNE and 
MIP-2. Z-α1PI was always purified with these columns as this protein did not bind to the 
PrepEase Histidine-tagged Protein Purification columns (Affymetrix). 
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3.2.2.2 PrepEase Histidine-tagged Protein Purification - High Specificity   
(Affymetrix) 
The Ni
2+
 ions are bound to the dry silica-based resin via the chelating group tris-
carboxymethyl ethylene diamine. Purification was performed according to the 
manufacturer’s instruction. If a Tris-based buffer was needed in subsequent steps, then all 
buffers after the first wash were replaced by Tris-based buffers. These columns are good 
for fast purifications. The Histidine-tagged PrepEase Protein Purification columns MIDI 
(Affymetrix) were used to purify 50-250 ml supernatant as the maximum binding 
capacity of His-tagged proteins is 2.5 mg. 
3.2.2.3 Ni-NTA Spin Kit (QIAGEN) 
Ni-NTA spin columns are especially good for small sample volumes. The PrepEase 
Ni-NTA uses a silica-based resin, but has a different chelator, nitrilotriacetic acid (NTA). 
Compared to the PrepEase Ni-NTA binds the proteins stronger and higher concentrations 
of imidazole are required to elute the proteins. The 300 µg binding capacity however, is 
the lowest of all three columns. The columns were used for supernatants below 50 ml 
according to the manufacturer’s instruction. 
3.2.3 Activation of NSPs by enterokinase cleavage 
Active NSPs may exert a toxic effect to the host cells and are therefore expressed in an 
inactive zymogen form. To keep them inactive, an N-terminal artificial propeptide is 
fused to the mature protein via an enterokinase cleavage site (D4K). The salt bridge 
between the N-terminus Ile
26
 and Asp
194
 is necessary for an active NSP and can only form 
upon removal by propeptide with the enterokinase. For optimal enterokinase activity the 
reaction was always performed in 20 mM Tris and 300 mM NaCl at neutral pH (pH 7.4). 
Two different enterokinases were used. When the enterokinase from New England 
Biolabs was used 2 mM CaCl2 is added to the normal enterokinase buffer to gain the full 
activity. The target protein should have a concentration of 0.3 -1.0 mg/ml. The ratio target 
protein to enterokinase (2 µg/ml) was always 1:14000. After the addition of the 
enterokinase (NEB) the digest was incubated at  37°C for two hours. The enterokinase 
from Roche did not need the addition of CaCl2. The target protein should have a 
concentration between 0.3 -1.0 mg/ml. The enterokinase is than added at a ratio of 1:40 
and incubated for two hours at 37°C. 
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3.2.4 Spectrophotometric quantification of proteins 
The amino acid tryptophan, and to some extent tyrosine and cystine bonds absorb 
UV-light at a wavelength λ= 280 nm. The number and extinction coefficient of these 
amino acid residues in each protein is therefore very important for protein quantification 
and expressed by the molar extinction coefficient (ε) [M
-1
cm
-1
]. After measuring the 
absorbance (A) the concentration (c) can be calculated using the Lambert-Beer law 
(Eq. 1). The path length (l) is normally 1 cm when using standard cuvettes. The free 
program ProtParam Expasy (SIB Swiss Institute of Bioinformatics) was used to 
determine ε from the amino acid sequence. 
Eq. 1 
c=
 
   
 
3.2.5 Quantification of proteins with bicinchoninic acid (BCA) assay 
Peptide bonds in proteins reduce Cu
2+
-ions to Cu
+
-ions. Cu
+
 in turn forms a chelate 
complex with two BCA-molecules which absorbs at λ= 562 nm. BCA assay of Uptima 
was used according to the manufacturer’s instructions. 
3.2.6 Enzyme-linked immunosorbent assay (ELISA) 
ELISAs are used to detect and quantify specific target proteins in complex solutions with 
the help of specific antibodies. There are direct and indirect “sandwich” ELISAs. In a 
sandwich ELISA a target specific antibody is coated on the plate to capture the desired 
protein from the sample. A second horseradish peroxidase (HRP) coupled antibody which 
is also directed against the specific protein is used for detection. The HRP oxidizes the 
substrate 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) The product of 
this reaction absorbs at λ= 405 nm.   
MIP-2 Standard ELISA Development Kit (Preprotech) was used according to the 
manufacturer’s instruction, because MIP-2 does not have any tryptophanes, which are 
necessary for reliable quantification through absorbance. 
 
c concentration 
A absorbance 
   molar extinction coefficient 
l pathway length 
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3.2.7 Discontinuous gel electrophoresis 
Similar to agarose gels, polyacrylamid gels are used to separate proteins by size and 
charge. Because proteins, unlike DNA, do not have a common charge, sodium dodecyl 
sulfate (SDS) is used to charge all proteins negatively. To avoid an influence of the 
protein structure on the separation, the proteins are denatured and disulfide bonds are 
reduced with β-mercaptoethanol. This method is called SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) under reducing conditions. 
Most of the time 15% Tris-glycine gels were employed, but for the separation of small 
fragments (5-10 kDa) 18% Tris-tricine SDS-polyacrylamide gels with 5% crosslinker 
were used. Gels were always poured between two glass plates with 1 mm spacer (Biorad). 
The resolving gel is always poured first and then overlayed with water to get an even 
edge. After the gel has completed the polymerization reaction, the stacking gel is poured 
and the combs for pockets are inserted. Tris-tricine gels were always run with different 
cathode and anode buffer (200 mM Tris-HCl, pH 8.8). The 10 x cathode buffer was 
purchased from Sigma-Aldrich (T1165). 
15% Tris-tricine SDS gel 
 stacking gel resolving gel 
H2O 2.5 ml - 
40% acrylamide/bisacrylamide (29:1) 0.5 ml - 
40% acrylamide/bisacrylamide (19:1) - 3.6 ml 
3 M Tris-HCl, pH 8,45; 0,4% SDS 1 ml 2 ml 
10% APS 16 µl 32 µl 
TEMED 16 µl 12 µl 
bromophenol blue - 0,2% (w/v) 
Tris-glycine running buffer 
50 mM Tris,  
384 mM glycine 
0,2% SDS 
pH 8.6 
 
 
 
Material and methods 
- 22 - 
 
Tris-glycine SDS gel 
 stacking gel resolving gel 
H2O 9.4 ml 13.6 ml 
40% acrylamide/bisacrylamide (37,5:1) 20 ml 3.32 ml 
1 M Tris-HCl, pH 6,8 10 ml - 
1,5 M Tris-HCl, pH 8,8 - 2.56 ml 
20% SDS 200 µl 100 µl 
10% APS 400 µl 200 µl 
TEMED 18 µl 16 µl 
bromophenol blue - 0,2% (w/v) 
4x loading dye 
200 mM Tris-HCl, pH 6,8 
10% SDS 
40% glycerol 
30% β–mercaptoethanol 
0,2% bromophenol blue 
3.2.8 Staining of protein gels 
To stop diffusion of proteins from the gels after electrophoresis, a fixation buffer with 
high organic solvent content is used at low pH. These conditions cause the proteins to 
unfold and their exposed hydrophobic parts interact and mediate the formation of forming 
insoluble complexes.  
3.2.9 Coomassie blue staining 
Directly after the discontinous gel electrophoresis the gel was incubated in the staining 
solution at room temperature for 1 hour. Afterwards the gel was incubated in the 
destaining solution at room temperature until the gel was destained to satisfaction and the 
bands clearly visible.  
Staining solution 
0.25% Coomassie Brilliant Blue R-250 
45% methanol 
10% acetic acid 
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Destaining solution: 
45% methanol 
10% acetic acid 
3.2.10 Silver staining 
The gel is first fixated at room temperature for an hour. After three washes of 20-min 
duration in 50% ethanol, the gel is incubated in a thiosulfate solution (0.2 g/l 
Na2S2O3x5H2O) for one minute. The gels are washed three times before and after putting 
the gel in the silver solution. A stop solution is added when the staining is satisfying. For 
long term storage keep the gel in 50% methanol. 
Fixation solution 
500 ml methanol 
120 ml acetic acid 
0, 5 ml 37% formaldehyde 
 Fill up to 1 L with H20 
Silver staining solution 
0,2 g silver nitrate 
75 µl 37% formaldehyde 
 Fill up to 100 ml with H20 
Developing solution 
60 g sodium carbonate 
4 mg sodium sulfate 
0.05 ml 37% formaldehyde 
 Fill up to 1 L with H20 
Stop solution 
500 ml methanol 
120 ml acetic acid 
 Fill up to 1 L with H20 
3.2.11 Western blot 
After SDS-PAGE protein bands are blotted on a membrane. A vertical electrical field 
causes the proteins to migrate out of the gel onto the membrane. The membrane is made 
Material and methods 
- 24 - 
 
out of polyvinylidene fluoride (PVDF), which binds protein via hydrophobic interactions. 
Before use the membrane has to be activated with 100% methanol. There are two 
different types of blotting: semi-dry and tank-blot. 
While the gel and the membrane is totally immersed in buffer during tank blotting, the 
membrane and gel are only wetted with buffer and fixed between two graphit plates 
during semi dry blotting. It is very important to remove air bubbles between the 
membrane and gel, because proteins can’t be transferred across air. The membrane was 
blocked with 5% (w/v) Non-Fat Dry Milk Blocker (Bio-Rad) in PBS-T at room 
temperature for one hour. The first antibody was incubated overnight at 4°C. Before and 
after incubation with the second antibody (room temperature, 1 hour) the membrane was 
washed three times with PBS-T for ten minutes. For the development WestPico (pierce) 
was used according to the manufacturer’s instruction.  
When more than one antibody was used for one membrane, the membrane is shortly 
washed with PBS-T after developing. Then the membrane is incubated in stripping buffer 
at room temperature for 30 minutes. Afterwards the membrane is washed thrice with 
PBS-T for 5 minutes to remove the stripping buffer. The membrane was then blocked 
with 5% (w/v) Non-Fat Dry Milk Blocker (Bio-Rad) at room temperature for 1 hour, 
before the new antibody was added. 
Western transfer buffer 
150 mM glycine 
35 mM Tris 
 pH 8.3 
 PBS-T  
 
 
 
140 mM NaCl 
2.7 mM KCl 
3.2 mM Na2HPO4  x 12 H2O 
1.5 mM KH2PO4 
0.05% (v/v) Tween 20 
 pH 7.4 
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Stripping buffer 
200 mM glycine 
0.1% (w/v) SDS 
 pH 2.2 
3.2.12 Activity assay 
A typical substrate for activity measurements always features a short peptide sequence 
linked to a chromophor or fluorophor, which can be only detected after its release by 
proteolytic cleavage via absorbance or fluorescence measurement. All quantifications 
were performed in activity buffer at room temperature. 
Activity buffer 
50 mM Tris-HCl, pH 7,4 
150 mM NaCl 
0.01% Tween 20 
3.2.12.1 Absorbance 
In this work p-nitroanilide (pNA) and thiobenzyl ester (SBzl) were the only chromophors 
used. Only when the amide bond between pNA and the C-teminus of the peptide is 
cleaved a change in the absorbance at 405 nm occurs. Therefore, there is only one 
possible cleavage site that results in a detectable signal. The cleavage of the thiobenzyl 
ester (1 mM) cannot be detected directly. To monitor the reaction at 405 nm, you add 
5,5´-dithiobis-(2-nitrobenzoic acid) (DTNB; 0.5 mM), which is hydrolised  to the 2-nitro-
5-thiobenzoate anion in the presence of free thiols. The working concentration for pNA is 
0.5 mM. 
3.2.12.2 Fluorescence 
Förster resonance energy transfer (FRET)-substrate consist always of a fluorescence and 
quencher group. The fluorochrome, 2-aminobenzoyl (Abz) or 4-methylcoumarinyl-7-
amide (Mca) is linked to a quencher, 2,4-dinitrophenyl (Dnp) or N-(2,4-
dinitrophenyl)ethylenediamine (EDDnp) via a short peptide. Once the peptide is cleaved 
internally in the fluorochrome and quencher groups are separated and the fluorescence 
can be measured (excitation: 320 nm, emission: 405 nm). In this case the cleavage is not 
clearly restricted to a single peptide bond within the given peptide sequence. 
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The fluorochrome 7-amido-4-methylcoumarin (AMC) is attached to the C-terminal site of 
a peptide. Only when this amide bond is cleaved, 7-amino-4 methylcoumarin is released, 
which can then be detected (excitation: 350 nm, emission: 450 nm). This means that only 
one possible cleavage site exists. 
3.2.13 Immunoprecipitation of MIP-2 
PMNs were stimulated with 10 ng/ml TNF-α (Biosource; PMC3016), 200 ng/ml phorbol 
myristate acetate (PMA) (Sigma; P1585) and 40 ng murine MIP-2 (Preprotech, 250-15) 
and incubated at 37°C for four hours. The suspension was centrifuged (600 g, 15 min) 
and the supernatant take for further analysis. After the addition of 10 µg anti-MIP-2 
anitbody (Preprotech, 500-P130) to the supernatant, the reaction was incubated at 4°C 
over night. To purify the MIP-2-antibody complexes 30 µl of pre-washed dynabeads 
Protein G (life technologies, 10004D) were added and incubated at 4°C for four hours. 
The beads were washed twice with PBS-T and then boiled in reducing sample buffer for 
SDS-PAGE. 
3.2.14 Preparation of PMNs lysate 
The cells were resuspended in RIPA buffer (3*10
4
 cells/µl) to lyse them. After incubation 
on ice for 15 min, the cells were put thrice into an ultrasonic bath for 5 min. In between 
the sonification, the cells are cooled on ice for 5 min. In the end the cells are centrifuged 
at 20000 g for 5 min to remove cell debris and DNA. 
RIPA buffer  
50 mM Tris-HCl pH 8.0 
150 mM NaCl 
0.5 M EDTA 
1 mM PMSF 
0.5% (w/v) Deoxycholic  acid 
0.1% (w/v) SDS 
0.5% (v/v) Nonodet P-40 
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3.3 Kinetic methods 
3.3.1 Burst titration 
During burst titration the substrate reacts in a suicide mechanism with the protease 
molecule, thereby inhibiting the protease in the process. Each substrate molecule reacts 
only with one protease molecule. Trypsin was titrated with p-nitrophenyl-p-
guanidinobenzoate. The amount of p-nitrophenol (ε= 8800 M
-1
cm
-1
) released equals the 
amount of trypsin and can be calculated by measuring the absorbance at 410 nm. 
3.3.2 Titration 
Titrated trypsin was used to determine the amount of active α1PI, which in turn was taken 
to determine concentration of sc- and tc-mNE. To fulfill the requirements, the 
concentration of the protease had to be at least 100-times higher than the dissociation 
constant Ki of the protease and α1PI. Trypsin was always used at 200 nM (Ki = 0,63 nM, 
(Hopkins et al., 1993)). Ki from mNE is not yet known, but judging from the Ki of hNE 
and antitrypsin (Ki = 330 pM, (Beatty et al., 1984), I used a concentration of 5-10 µM for 
mNE. In all experiments, inhibitor concentration was varied, while the protease 
concentration was kept constant. Remaining protease concentration activity was 
measured after incubation for one hour at 37°C. Plotting the inhibitor concentration 
against the relative velocity renders a linear regression. The intersection with the x- axis 
can be obtained by extrapolation. The x-axis intercept indicates the concentration of the 
protease in the sample. 
3.3.3 KM and kcat 
The reaction of an enzyme E converting a substrate S to a product P can be described 
with equation 2 (Berg et al., 2003). The reaction is divided into two parts. First the 
substrate (S) and enzyme (E) form a reversible complex (ES), then the substrate is 
cleaved, which leads to the product (P). 
Eq. 2 
E enzyme 
S substrate 
ES enzyme-substrate complex 
P product 
E+S ES E+P
k
1
k
-1
k
2
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This reaction is described by the Michaelis-Menten equation (Eq. 4) (Berg et al., 2003). 
The Michaelis Menten (KM) concentration is the concentration of the substrate at which 
the half-maximum velocity is reached. Together with the catalytic constant (kcat) this is an 
important parameter to judge, how well a substrate fits the enzyme. When all enzymes are 
binding a substrate then kcat can be calculated with Eq. 3: kcat=vmax/[E]. [E] is the total 
enzyme concentration. 
Eq. 4 
   
        
      
 
In this study we always used 23 nM sc-mNE or 231 nM tc-mNE respectively for the 
determination of KM. Substrate concentrations [S] were varied from 1-80 µM and plotted 
against the reaction rate (v) and fitted to the Michaelis-Menten equation using GraphPad 
Prism (GraphPad Software, Inc., La Jolla). 
3.3.4 Competitive inhibition  
In this kind of inhibition, the inhibitor competes with the substrate for the enzyme. So 
enhancing the substrate concentration influences the inhibition. The maximum velocity 
vmax can still be reached, given [S] is high enough, but KM increases with higher 
inhibition concentration [I] (Berg et al., 2003). For competitive inhibitors the inhibitor 
constant Ki is the same as the dissociation constant KD. 
Eq. 5 
 
v velocity 
vmax maximum velocity 
[S] concentration of substrate at any time 
KM Michaelis-Menten constant 
E enzyme 
S substrate 
ES enzyme-substrate complex, reversible 
P product 
I inhibitor 
EI enzyme-inhibitor complex, reversible 
 
 E+
S +
I 
EI 
ES E+P 
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The relation between [I] and KM can be described as follows (Berg et al., 2003): 
Eq. 6 
 
  
 
 
    
 
  
    
(  
   
  
) (
 
   
) 
Through different Michaelis-Menten curves and by varying inhibitor concentrations, one 
can calculate the inhibitor constant Ki. 
3.3.5 Irreversible inhibition  
An irreversible inhibitor first forms a reversible complex with the enzyme. As soon as the 
protease has cleaved the inhibitor, an irreversible complex is formed. The substrate 
concentration only influences the first reaction, but not the second. So higher substrate 
concentrations can delay the inhibition but cannot completely abrogate it as seen in 
competitive inhibition. In an irreversible inhibition Vmax is changed, while KM remains the 
same. 
Eq. 7 
E+I EI EI*
k
1
k
-1
k
2
 
The reaction of α1PI and NE is too fast for conventional Ki determination. Therefore 
different concentrations (50-300 nM) of inhibitor were mixed with 100 µM substrate 
before adding the protease. The resulting curve can be described with equation 7 
(Duranton and Bieth, 2003). 
 
 
 
 
 
 
v velocity 
vmax maximum velocity 
[S] concentration of substrate at any time 
KM Michaelis-Menten constant 
E enzyme 
I inhibitor 
EI reversible enzyme-inhibitor complex  
EI* irreversible enzyme-inhibitor complex  
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Ki(app) apparent inhibitor concentration 
[S] concentration of substrate at any time 
Ki
*
 equilibrium dissociation constant 
KM Michaelis-Menten constant 
Eq. 8 
    (
  
    
) (          ) 
The substrate concentration was five times higher than KM, so no substrate depletion 
occurred. To ensure that inhibitor concentration was not significantly changed at least 
five times higher inhibitor than enzyme concentration was used. Fitting the curves in 
GraphPad Prism to equation 7 provided us with the observed rate constant (kobs). Then 
kobs values were plotted against inhibitor concentration and the resulting curve was fitted 
to following equation 8 and 9 (Duranton and Bieth, 2003). 
Eq. 9 
     
      
            
 
Eq. 10 
          
 (  
    
  
) 
 
 
 
 
 
EI* does not accumulate significantly at inhibitor concentration well below the 
equilibrium dissociation constant Ki*(Ki*= k-1/k1) . In this case the inhibition behaves like 
a simple bimolecular reaction (E + I → EI) (Duranton and Bieth, 2003) and equation 10 
applies. This reaction is governed by a second-order association constant kass. 
 
v0 velocity at time point zero 
kobs observed rate constant 
[P] concentration of product at any time 
Ki(app) apparent inhibitor constant 
k2 first-order rate constant  
[I]o concentration of inhibitor at time point zero 
 
kobs observed rate constant 
Ki(app) apparent inhibitor constant 
k2 first-order rate constant 
[I]o concentration of inhibitor at time point zero 
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kass second-order association constant 
k2 first-order rate constant 
Ki
*
 equilibrium dissociation constant 
Eq. 10 
     
  
  
  
3.4 Cell biological methods 
3.4.1 Cell culture 
Expression was done in HEK-EBNA cell lines. This cell line is derived from primary 
human embryonic kidney cells that were transformed with adenovirus type 5. In addition, 
this cell lines has a codon optimized fusion protein EBNA1, which consists of a truncated 
nuclear protein of the Epstein-Barr virus EBNA1c and a protein from the Herpes Simplex 
virus VP16. EBNA1 enables the replication of plasmids that possess an oriP in 
mammalian cells. For expression the pTT5 expression system was used. 
HEK 293 EBNA cells were cultured in serum free media (Gibco® FreeStyle™ 293 
Expression Medium, (Life technologies) to reduce the amount of undesired proteins. 
Foam reducing agent Pluronic F-68 (0,1%) and geniticin selective antibiotic (G418 
sulfate, 25 µg/ml) were also added to the medium. 
3.4.2 Transfection 
The proteins were expressed in the HEK 293 EBNA 1 cell line. The cells were cultured in  
FreestyleTM 293 Expression Medium (Invitrogen) with 0.1% (v/v) Pluronic® F-68 and 
25 μg/ml Geneticin® G418. Cells are diluted to a concentration of 1*10
6
 cells per ml 
before transfection. The amount of DNA used for a transfection is proportional to the 
amount of transfected cells (for x ml cells, x µg DNA and 2 x µl polyethylenimine (PEI) 
is used). First DNA and PEI (1 mg/ml) are diluted separately in an equal volume of 
OptiPro (Life technologies) (70 µl OptiPro per one ml cell suspension). After mixing the 
OptiPro-PEI and OptiPro-DNA solutions together complexes are forming at room 
temperature within the next 20 min. The transfection solution is than added drop by drop 
to the cells. To stabilize the recombinant proteins in the supernatant 0.5% (v/v) Bacto TC 
Lactalbumin Hydrolysate (BD Biosciences) is added after 24 hours. 
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3.4.3 Isolation of granulocytes 
3.4.3.1 Human granulocytes 
Human granulocytes were isolated from whole blood on a discontinuous Ficoll gradient. 
To avoid coagulation of the blood, ethylenediaminetetraacetic acid (EDTA) covered 
syringes were used. EDTA-blood was diluted to a final volume of 40 ml with PBS and 
carefully underlayed with 10 ml Pancoll (δ=1,077 g/L). The high density of Pancoll 
ensures that only erythrocytes and granulocytes can cross through this layer during 
centrifugation (500 g, at RT, without brake for 30 min). After removing the supernatant 
containing PBMCs the erythrocytes are removed in two steps. First, we used dextran 
sedimentation for 30 minutes (1% dextran), to roughly separate the cells, as erythrocytes 
settle down faster. The supernatant is then centrifuged (1200 rpm, at RT for 15 min). To 
remove the remaining erythrocytes, the pellet is resuspended in 5 ml 0.2% NaCl solution 
for one minute, before 5 ml of 1.6% NaCl solution is added and everything is incubated 
again for a minute. The cell suspension is filled with PBS to 50ml and then centrifuged 
(1350 rpm, at RT for 5 min). A washing step with PBS follows (centrifuge 1350 rpm at 
4°C, for 5 min). If necessary, the lysis can be repeated. 
3.4.3.2 Murine granulocytes 
The small size of a mouse and the corresponding small blood volume makes the isolation 
of murine PMNs (mPMNs) difficult. Better sources for mPMNs are bone marrow cells. 
Both femurs are flushed with PBS and the suspension centrifuged at 1200 rpm for 5 min. 
Cells were resuspended in 10 ml PBS and send through a cell strainer (BD biosciences). 
On the bottom of the discontinuous gradient is a 62% percoll solution (5.69 ml 10x HBSS 
+ 9.32 ml percoll) and on top is the cell suspension. After centrifugation (30 min, 300 g, 
RT, without brake) the granulocytes and erythrocytes are in the cell pellet, while the 
PBMCs are left in the supernatant. The supernatant is carefully removed and a hypotonic 
lysis performed by resuspension of the cells in lysis buffer (9 ml 0.8%. NH4Cl, 1 ml Tris-
HCl pH 7,4). The cells are finally washed with PBS. 
3.4.4 Identification of sc- and tc-NE in biological samples 
Identification of human NE in human samples was done in two steps. The lysate of 3*10
6
 
hPMNs (100 µl lysate), was inhibited with 20 nmol biotinylated NE-specific AAPV-
chloromethyl ketone inhibitor (CMK) at 37°C for 30 min. The inhibitor reacts covalently 
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with NE. Then 4,4 µg anti-hNE antibody (QED, Cat.No.12303) was added and incubated 
overnight at 4°C. HNE-antibody complexes were captured with Protein G dynabeads 
(Life sciences). For analysis on a SDS-PAGE the beads were boiled at 95°C in reducing 
sample buffer for 5 min. Because of the biotin, the inhibited hNE could be detected with 
HRP-coupled streptavidin after SDS-PAGE. In murine samples mNE could be detected 
directly by western blot analysis, using an anti-hNE antibody (Abcam, Cat.No. ab68672) 
that cross reacts with mNE.  
3.4.5 Chemotaxis assay 
For a comparison of two chemokines the under-agarose-assay is the method of choice, 
because it allows a direct comparison of different chemokines in one experiment. An 
agarose layer is pured into a 35 mm dish.  Holes with a distance between 2-4 mm are 
punched into the agarose layer for cells and chemokines. The dishes are incubated at 
37°C and 5% CO2 prior to the experiment. The cells are placed between the two 
chemokine reservoirs. In each experiment 7 µl of 0.1 mg/ml chemokine were put into a 
well and 7 µl of PMNs suspension (2.4 *10
7
 cells/ml). The experiment has to be done at 
37°C and in an atmosphere of 5% CO2, because the agarose is buffered with bicarbonate. 
The cells can sense the chemokine gradient and start to wander under the agarose. This 
can be monitored with an optical microscope (20 x magnifications) and after 4-6 hours a 
picture is taken. 
 
Fig 3.1: Under agarose assay In an agarose layer of a petri dish with 35 mm diameter holes for the 
PMNs and chemokines are punched. After the PMNs and the chemokines are filled in, the PMNs start 
crawling between the agarose layer and the bottom of the petri dish towards the chemokine. A picture 
with an optical microscope is taken and the cells are counted. The grey boxes mark the fields in which 
the cells are counted. 
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Agarose layer 
5 ml 2 x HBSS (Gibco®, life sciences) 
10 ml RPMI + 20%FCS (Gibco®, life sciences) 
0.2 g Agarose LE (Biozym) 
10 ml H2O 
3.4.6 Flow cytometry 
The cell suspension is focused in a liquid stream that only one cell at a time passes the 
laser beam. By means of light scatter, density and size of a cell can be determined. 
Expression of different markers can be identified by staining the cells with fluorescently 
labeled antibodies.  
For each staining 1*10
5
 cells were used. The first antibody is diluted to a concentration of 
2 µg/ml in PBS + 1% BSA and incubated at 4°C for 30 min. After three washes the cells 
with PBS the second antibody (2.5 µg/ml) was added to the cells and incubated at 4°C in 
the dark for 30 min. Cells were washed thrice again with PBS. Propidium iodide is added 
in the last washing step before analysis. At last cells were resuspended in 200 µl PBS. 
Phosphate buffered saline (PBS) 
136,89 mM NaCl 
2,68 mM KCl 
9,47 mM Na2HPO4 
1,76 mM KH2PO4 
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4 Results 
4.1 NSP regulate inflammation by processing of chemokines 
4.1.1 N-terminal processing of MIP-2 by NE and PR3 in-vitro 
4.1.1.1 Production of recombinant mPR3 and mNE 
Murine PR3 and NE (mPR3 and mNE) were expressed in HEK293 EBNA cells using the 
pTT5 expression vector. As secretion of the proteases in the supernatant was desired, an 
N-terminal Igκ-signal peptide was added (Fig 4.1 A). Using a C-terminal His-tag, the 
Fig 4.1: Production of recombinant mPR3 and mNE. (A) Both proteases (black, loosely hatched 
bar) were expressed in HEK293 cells with a C-terminal His-tag (black box) for purification. To 
prevent premature activation of these proteases, which would be toxic to the cells, an artificial 
propeptide (black, tightly hatched box) was added to the N-terminus. For removal of the propeptide 
an enterokinase (EK) cleavage site (vertical line, labeled EK) was inserted before the mature 
N-terminus of the NSPs. The exact sequence can be found in the appendix (8.2.1 and 8.2.2). (B) 600 
ng pro-mPR3 before (left lane) and after (right lane) the addition of enterokinase, were compared on a 
silver stained gel. Although pro-mPR3 (band 2) was purified still some unknown proteins can be seen. 
Besides mature mPR3 (band 3) EK was detected (band 1) as EK has not been removed. (C) Five µg 
purified pro-mNE (band 4) before enterokinase was added were loaded on the left lane of the 
Coomassie stained gel. Three µg of mNE after EK digest and removal of EK were loaded on the right 
lane. The middle lane contains the prestained protein marker (NEB, P7708). In addition to the mature 
mNE (band 5) two smaller bands appeared (band 6,7). These bands are fragments of mNE and will be 
discussed later. Both gels were 15% SDS gels. 
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NSPs were purified with Ni-columns from the supernatant. Depending on the amount of 
supernatant different columns were used (see chapter 3.2.2). To protect the cells from the 
toxicity of the NSPs an artificial propeptide followed by an enterokinase cleavage site 
(DDDDK) keeps the protease inactive. Just like natural occurring zymogens, the artificial 
propeptide prevents the formation of the active conformation, the opening of the S1 
pocket and generation of the oxyanion hole. Purification of NSPs from the supernatant 
yielded very clean fractions (Fig 4.1 B, C). The removal of the propeptide with 
enterokinase results in a size shift that is visible in a reducing 15% SDS-PAGE. The 
conversion of the zymogens was successful and complete, but for mNE I had three bands 
instead of one band were observed after the conversion. Band 1 is the mature intact form 
of mNE. The two lower bands 2, 3 are products of the self-cleavage of mNE as will be 
shown and discussed in detail later (4.2).  
4.1.1.2 N-terminal processing of MIP-2 by neutrophil proteases 
Murine MIP-2 with a concentration of 0.2 mg/ml (Preprotech) (mMIP-2) was incubated 
with either recombinant mPR3 or mNE (19 µg/ml) at 37°C for one hour in PBS. In the 
core facility of the MPI Biochemistry, Elisabeth Weyher examined the mixture using 
mass spectrometry analysis. Both mPR3 and mNE were able to cleave mMIP-2 after 
alanine at position four (Fig 4.2 A), which is similar to the cleavage site of hPR3 in 
human. As previously mentioned, processing of human IL-8 by hPR3 as well as by 
MMP-8 and MMP-9, enhances the chemotactic ability of IL-8 (Mortier et al., 2008; 
Padrines et al., 1994). MMP-12, which is found predominantly in macrophages, destroys 
the ELR-motif of hIL-8, which is essential for its CXCR2 binding capacity. This results 
in the inactivation of human IL-8. Given that hIL-8 can also be processed by MMPs, I 
used the fluorescence substrate Abz-GAVVASELR-Y(NO2)-D that features the N-
terminal sequence of MIP-2 to test processing of mMIP-2 by other endoproteases of 
PMNs (Fig 4.2 B). Cleavage at any position of the peptide results in the generation of a 
fluorescence signal. The negative control consists only of substrate and buffer, while hNE 
was added as a positive control. As expected, PMN lysate from wt mice was able to 
cleave the substrate, because it contains mPR3 and mNE. PMN lysate from PR3/NE 
deficient mice was no longer able to generate a signal, thus the only endoproteases 
capable of processing mMIP-2 in neutrophils are mPR3 and mNE. 
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To simulate a more in vivo-like situation, I isolated mPMNs from the bone marrow and 
stimulated them with TNF-α. Then I added MIP-2 and incubated this at 37°C for 4 hours. 
After an immunoprecipitation with anti-MIP-2 antibodies (Preprotech), I blotted the 
purified MIP-2 on a membrane for Edman sequencing. I was able to detect MIP-2(5-73) 
only with wt, but not with PR3/NE deficient mPMNs. The experiment was repeated 
thrice. 
4.1.2 Chemotactic properties of MIP-2 
4.1.2.1 Comparison of processed and intact mMIP-2 
 As already mentioned, PR3 processed hIL-8 is a more chemotactic form of hIL-8, so 
processed mMIP-2 might also change its chemotactic properties. The under-agarose-
assay enabled me to compare unprocessed and processed mMIP-2 in one experiment. In a 
agarose layer holes were punched for the cells and chemokines. Between the chemokines 
Fig 4.2: mNE and mPR3 are the only endoproteases processing MIP-2. (A) Chemotactic property 
of IL-8 is enhanced after the processing by MMP-8, MMP-9 and hPR3 in-vitro. By contrast, cleavage 
of MMP-12 inactivates hIL-8. I incubated mMIP-2 (0.2 mg/ml) with mPR3 or mNE (19 µg/ml) and 
gave the digest for mass spectrometry analysis to E. Wehyer (MPI Biochemistry). A cleavage site at 
Ala
4
 was found, which is comparable to the cleavage site where hPR3 processes hIL-8. (B) A 
substrate covering the N-terminal sequence of mMIP-2 (Abz-GAVVASELR-Y(NO2)-D) was 
incubated with the lysate of from 1.5*10
6
 wt (filled, black squares) and PR3/NE deficient mPMNs 
(hollowed, black squares). Once the substrate is cleaved the quencher and fluorescent groups are 
separated, the fluorescence was measured (excitation: 320 nm, emission: 405 nm). Only wt (black 
squares) but not PR3/NE deficient (white squares) mPMNs were able to cleave the substrate, meaning 
other proteases of mPMNs were not able to cleave the N-terminal sequence of mMIP-2. The negative 
control (grey dots) consisted of substrate alone. For a positive control (grey squares) hNE was added 
to the substrate. Data (mean ± SD) are representative of 3 independent experiments each conducted in 
triplicate. The y-axis shows the fluorescence in relative fluorescence units (RFU). 
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(7 µl with the concentration 0.2 mg/ml) 7 µl of 2.4*10
7
 mPMNs were placed. After 4-6 
hours a pictures were taken with an optical microscope (20 x magnifications) and the 
migrated cells were counted. The cell count was very heterogenous from experiment to 
experiment with 113-247 cells migrated mPMNs as the highest cell numbers. For better 
comparison cell count was normalized, with the highest cell count set to 100%. Unaltered 
mMIP-2 (MIP-2(1-73)), a mixture of mPR3 and mMIP-2 and PR3 alone were tested at 
the same time during one experiment (Fig 4.3 A). Almost none mPMNs migrated towards 
the negative control, mPR3, because mPR3 itself is not chemotactic (8%) (Fig 4.3 B). A 
moderate amount of cells (20%) crawled towards mMIP-2(1-73), while five times more 
PMNs responded to processed MIP-2 (MIP-2(5-73)). Murine MIP-2 that was processed 
by mPR3 is therefore clearly more chemotactic than intact MIP-2(1-73). 
 
4.1.2.2 Production of processed and intact MIP-2 
 Only MIP-2(1-73) is commercial available at present. Therefore it was necessary to 
express both forms of mMIP-2 in our lab for further experiments. As described for NSPs, 
both mMIP-2 forms were expressed in HEK293 EBNA cells. The constructs consisted of 
an Igκ-signal peptide and a C-terminal his-tag (Fig 4.4 A). I was able to express and 
purify clean MIP-2(5-73) with a correct N-terminus (Fig 4.4 B), verified by Reinhard 
Fig 4.3: Processing of MIP-2 enhances its chemotactic activity. For the comparison of chemokines, 
7 µl mPMNs (2.4*10
7
 cells/ml) are placed between the chemokines (0.2 mg/ml) into holes in an 
agarose layer. The mPMNs can sense the chemokine gradient and start to crawl under the agarose 
towards the chemokine source. Using an optical microscope the migrated cells are counted. (A) The 
total cell count for mPR3 (light grey bar), intact MIP-2 (white bar) and processed MIP-2 (dark grey 
bar) were compared to each other. (B) As the cell number of migrated cells varied much between the 
experiments (113-247 PMNs for MIP-2+PR3), I normalized the cell count to the highest value, which 
was set to 100%. Processed MIP-2 attracted five times more mPMNs than intact MIP-2. Data (mean ± 
SD) are representative of 3 independent experiments.   
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Mentele (Core facility of MPI of biochemistry) via Edman Sequencing. Expression of full 
length MIP-2(1-73) without a propeptide was unsuccessful, as 30% of MIP-2(1-73) was 
shortened by one amino acid residue at the N-terminus. To protect the N-terminus of the 
MIP-2(1-73) against exopeptidases, a small propeptide with cleavage site for removal by 
enterokinase was added N-terminally to MIP-2(1-73). In order to apply equal treatment to 
both forms, I also tried to use the same propeptide with MIP-2(5-73). Unfortunately, the 
propeptide of MIP-2(5-73) could not be removed by enterokinase. This is the reason why 
I expressed MIP-2(5-73) without propeptide, while MIP-2(1-73) was expressed with a 
propeptide. I purified both forms of MIP-2 using either PrepEase MIDI columns or 
HisTrap
TM
 HP columns, depending on the amount of supernatant, and was able to get 
clean preparations of MIP-2 (B, C). Successful conversion of pro_MIP-2(1-73) with 
enterokinase was analyzed by SDS-PAGE and was demonstrated by Edman sequencing 
in the Core facility of the MPI Biochemistry (Reinhard Mentele). 
 
4.1.2.3 CXCR2 internalization after stimulation with MIP-2 
It is still unclear why MIP-2(5-73) is more chemotactic than MIP-2(1-73). One reason is 
the different receptor binding capabilities of the two MIP-2 forms. I isolated mPMNs 
Fig 4.4: Production of processed and intact MIP-2. (A) The pTT5/HEK293 expression system 
was used to produce two MIP-2 variants. Both constructs have a C-terminal his-tag (black bar) 
for purification. MIP-2(1-73) (white bar) has an additional propeptide (black, hatched bar) to 
protect it against exopeptidases from HEK293 cells. The propeptide ended with an enterokinase 
cleavage site, so the propetide could be removed precisely after purification. The sequence is 
listed in the appendix (8.2.3 and 8.2.4) (B) Purified MIP-2(5-73) (400 ng) was separated on a 
15% SDS gel and stained with silver. (C) The conversion of purified pro-MIP-2(1-73) by 
enterokinase was checked after SDS-PAGE and silver staining. 4.5 µg of pro-MIP-2(1-73) 
before and after the digest was loaded.  
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from wt mice and incubated 1*10
5
 mPMNs with 200 ng MIP-2(1-73), 200 ng 
MIP-2(5-73) or PBS at 37°C for 5 min. After the mMIP-2 variants bound to CXCR2, the 
MIP-2-CXCR2 complex was internalized, thus the amount of receptors on the surface 
was reduced (Fig 4.5 A). Murine PMNs were then stained with anti-CXCR2 receptor 
antibody (2 µg/ml) to quantify the remaining CXCR2 on the surface. As this antibody is a 
rat antibody, a FITC-coupled anti-rat antibody (2.5 µg/ml) was used for visualization in 
FACS. 
Before MIP-2 treatment, there were 38±1% CXCR2
 
positive PMNs (Fig4.5B). After 
incubation with MIP-2(1-73) and MIP-2(5-73), 9±4% and 10±3%, respectively, remained 
CXCR2
 
positive. In each experiment 10000 PMNs per population were counted. The data 
are mean ± SEM of three independent experiments. 
Fig 4.5: CXCR2 internalization after stimulation with MIP-2.  (A) 1*10
5
 Murine PMNs, 
isolated from the bone marrow, were first incubated with 200 ng MIP-2 or PBS at 37°C for 5 
min. After binding of MIP-2, receptors were internalized and therefore disappeared from the 
surface. Immediately after the incubation PMNs were stained with anti-CXCR2 (2 µg/ml) to 
detect the remaining CXCR2 (second antibody: FITC-coupled anti-rat; 2.5 µg/ml). (B) The 
CXCR2
+
-PMNs were counted after exposure to MIP-2(1-73) (red) and MIP-2(5-73) (blue) and 
compared to unstimulated PMNs (black). The left panel shows an example of such an 
experiment. The right panel shows a summary of all experiments. Both MIP-2 variants were able 
to induce receptor internalization. No significant difference could be discerned. Data shown are 
mean ± SEM from all experiments with n=3 and always 10000 cells were counted for each 
staining. 
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4.1.3 Further MIP-2 variants 
4.1.3.1 Production of further MIP-2 variants 
I produced fusion proteins between MIP-2 and two different fluorescence proteins, cherry 
and ruby, to visualize mMIP-2 processing in-vitro and in-vivo (Fig 4.6 A). As described 
above, constructs before, I expressed both fusion proteins in HEK293 EBNA cells by 
using an Igκ-signal peptide for secretion and a C-terminal his-tag for purification. In the 
first construct the fluorescence protein cherry was N-terminally fused to MIP-2(1-73) 
(Ch_MIP-2). Since the N-terminus is very important for chemotactic activity, I also made 
a construct in which the fluorescence protein ruby was inserted between MIP-2(5-73) and 
its his-tag (MIP-2_Ru) at the C-terminus. Both proteins were well expressed in HEK293 
EBNA cells and could be isolated from the supernatant in highly pure form using 
Fig 4.6: Production of further MIP-2 variants.  (A) As with the proteins described above, the 
pTT5/HEK293 expression system was used for recombinant production. Both MIP-2 constructs have 
a C-terminal his-tag (black bar) for purification and an Igκ-signal peptide (grey, hatched bar) for 
secretion. In the Ch_MIP-2(1-73) construct, the fluorescence protein cherry (white, hatched bar) has 
been placed N-terminal to MIP-2(1-73) (white bar), while for the MIP-2_Ru construct the 
fluorescence protein ruby (dark grey, hatched bar) has been C-terminally positioned to MIP-2(5-73) 
(dark grey bar). The sequence is listed in the appendix (8.2.5 and 8.2.6) (B) 3.3 µg purified Ch_MIP-
2 (band 1) was run on a 15% SDS polyacrylamide gel and stained with Coomassie. The additional 
lower band 2 is probably a degradation product resulting from an unwanted N-terminal cleavage in 
HEK-293. (C) MIP-2_Ru was purified and 560 ng was loaded on a 15% SDS gel that was stained 
with silver. 
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PrepEase MIDI columns or HisTrap
TM
 HP columns (B). Purification of Ch_MIP-2 
yielded a second band of approximately 26 kDa. Since this band still bound to the Ni-
column and co-purified with Ch-MIP-2, I suggest, that Ch_MIP-2 was nicked and 
shortened within the N-terminal region by endoproteases from HEK293 cells. 
4.1.3.2 Processing of Ch_MIP-2 with mNE or mPR3  
Cherry was linked to MIP-2(1-73) and initial cleavage by mPR3 or mNE separated cherry 
(28 kDa) from MIP-2(5-73) (7 kDa) (Fig 4.7 A, B). To see whether the cherry domain 
sterically blocks the cleavage site of mPR3 or mNE, I incubated 30 µg Ch_MIP-2 (Fig 
4.7, band 1) with 1.67 µg active mPR3 or mNE and ran an SDS-PAGE to analyze the size 
shift. After 10,20,30,60 and 120 min aliquots containing 4 µg Ch_MIP-2 and 222 ng 
protease were taken and immediately boiled with reducing sample buffer at 95°C. A band 
with the size of cherry appeared (Fig 4.7, band 2) after 10 minutes of incubation of 
Ch_MIP-2 with mNE. After 2 hours Ch_MIP-2 was completely cleaved and only cherry 
remained. MIP-2(5-73) was too small and was therefore not retained on this gel. The 
reaction with mPR3 was considerably slower, but still mPR3 was able to digest 
Ch_MIP-2 almost completely after 120 min. 
Fig 4.7: Processing of Ch_MIP-2 by mNE and mPR3. (A) For each experiment 1,67 µg mPR3 was 
incubated with 30 µg Ch_MIP-2 at 37° ( ratio of 1:18). At every time point an aliquot was retrieved 
and immediately boiled at 95°C with sample buffer. Each lane contains 4 µg Ch_MIP-2 and 222 ng 
mPR3. Ch_MIP-2 has a size of 35 kDa big (band 1) and is split into cherry (28 kDa) and MIP-2(5-73) 
(7 kDa) after cleavage. Only the bigger band of cherry (band 2) can be seen in this Coomassie-stained 
15% SDS polyacrylamide gel.  (B) The experiment from A was repeated with mNE instead of mPR3. 
30 µg Ch_MIP-2 was incubated with 1.67 µg mNE and aliquots containing 4 µg Ch_MIP-2 and 222 
ng mNE were retrieved at different time points. The aliquots were loaded on a Coomassie-stained 
15% SDS gel. Both mPR3 and mNE were able to cleave Ch_MIP-2 into cherry and MIP-2(5-73).  
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4.1.3.3 CXCR2 internalization after stimulation with MIP-2 variants 
As already mentioned the N-terminal extension of MIP-2 by cherry may influence its 
chemotactic ability. To investigate this, Ch_MIP-2 and MIP-2_Ru, which have about the 
same size, were compared to each other with regard to CXCR2 internalization (Fig 4.8). I 
incubated and stained wt mPMNs as described in chapter 4.1.2.3. Murine PMNs (1*10
5
) 
were incubated with equal amounts of Ch_MIP-2 or MIP-2_Ru (860 ng) at 37°C for 5 
minutes. Immediately afterwards the cells were cooled on ice and stained with anti-
CXCR2 antibody (2 µg/ml). The second antibody, FITC-coupled anti-rat antibody was 
used at a concentration of 2.5 µg/ml. While 32±9% of wt mPMNs had a high CXCR2 
expression, only 5±4% and 6±5% respectively, remained CXCR2 positive after 
incubation with either Ch_MIP-2 or MIP-2_Ru. 
 Since I expected Ch_MIP-2 to be inert, I repeated the experiments with PR3/NE 
deficient PMNs to exclude the activation of Ch_MIP-2 and MIP-2(1-73) to a more active 
form by mPR3 and mNE from wt PMNs (Fig 4.9 A). 
The PR3/NE deficient mPMNs were incubated and stained as described above (Fig 4.5 
and Fig 4.7). It was more difficult to define clear populations of CXCR2
+
 mPMNs (Fig 
4.9 B). I set a gate, so 11.1±0.4% of wt mPMNs were CXCR2
 
positive. As expected, 
incubation with MIP-2_Ru decreased the amount of CXCR2
+
-cells to 3.2±0.1%. 
Fig 4.8: Internalization of CXCR2 after exposure to MIP-2 variants. Murine wt PMNs (1*10
5
) 
from the bone marrow were incubated with 860 ng Ch-MIP-2 (red) or 860 ng MIP-2_Ru (blue) or 
PBS (black) at 37°C for 5 min, and then stained with anti-CXCR2 antibody (2 µg/ml). CXCR2 
density was determined by flow cytometry. The left panel show an example of such an experiment. 
The right panel shows the summary of all experiments. Data shown are mean ± SEM from all 
experiments with n=2. Ch_MIP-2 and MIP-2_Ru reduced CXCR2 positive population from 32(±2)% 
to 5(±4)% and 6(±5)% respectively. There was no significant difference between CH-MIP-2’s and 
MIP-2_Ru’s ability to invoke CXCR2 internalization. 
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Interestingly, Ch_MIP-2 did not change the levels of CXCR2 on the surface. I also 
repeated the comparison between MIP-2(1-73) and MIP-2(5-73) (Fig4.9 B). There was 
Fig 4.9: Different ability of Ch_MIP-2 and MIP-2_Ru to internalize CXCR2. (A) Wt mPMNs can 
use their own mPR3 and mNE to convert Ch-MIP-2 to its active form and wt mPMNs can therefore 
also convert MIP-2(1-73) to the more chemotactic form MIP-2(5-73).  To avoid this, the experiment 
from Fig 4.8 was repeated with PR3/NE deficient mPMNs. (B) Knockout PMNs (1*10
5
) from the 
bone marrow were incubated at 37°C for 5 min with 860 ng Ch-MIP-2 (red) or MIP-2_Ru (blue). 
Cells treated only with PBS are depicted black. The PMNs were stained with 2 µg/ml anti-CXCR2 
antibody (second antibody: FITC-coupled anti-rat antibody; 2.5 µg/ml). CXCR2 positive cells were 
counted and compared. Data shown is the mean ± SEM from all experiments with n=2. Only MIP-
2_Ru but not Ch_MIP-2 was able to induce CXCR2 internalization in PR3/NE deficient mPMNs (C) 
PR3/NE deficient mPMNs were incubated with 200 ng MIP-2(1-73) (red) or MIP-2(5-73) (blue) 
before they were stained with anti-CXCR2 antibody as described above. Data shown is the mean ± 
SEM from all experiments with n=4. There was no significant difference between MIP-2(1-73) and 
MIP-2(5-73). 
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no significant difference between those two MIP-2 variants. Both decreased the 
population of CXCR2
+
 cells from 31.3±0.5% to 4.2±2.8% (MIP-2(1-73)) or 3.4±2.0% 
(MIP-2(5-73).  
4.1.4 Other chemokines as substrates  
 Based on the known N-terminal sequences of three other CXC ELR
+
 chemokines, three 
fluorescence substrates were synthesized by EMC microcollections GmbH (A). After the 
cleavage of these substrates the fluorescence can be measured (excitation: 320 nm, 
Fig 4.10: Processing of other chemokines by mNE or mPR3. (A) There are three other murine CXC 
ELR
+
 chemokines that may also be processed by mPR3 and mNE. To answer this question, two 
additional FRET-substrates representing the N-terminus from the other chemokines were ordered.  
Cleavage of the substrates by mPR3 or mNE results in fluorescence that can be measured. (B) The 
LIX substrate Abz-GVIAATELR-Y(NO2)-D was incubated with lysates from 1.5*10
6
 wt (black 
squares) or PR3/NE deficient PMNs (white squares). The negative control was only substrate and 
buffer (grey dots). Data shown is the mean ± SEM of 3 independent experiments each conducted in 
triplicates. The LIX substrate is cleaved by the lysate of wt PMNs, but not by the lysate of PR3/NE-
deficient PMNs. (C) The KC substrate Abz-GAPIANELR-Y(NO2)-D is incubated with lysates from 
1.5*10
6
 wt (black squares) or PR3/NE deficient (white squeares) PMNs. The negative control was 
only substrate and buffer (grey dots). Data shown is the mean ± SEM of 3 independent experiments 
each conducted in triplicates. The KC-substrate is cleaved by lysate of wt and PR3/NE knockout 
lysate, although cleavage was more efficient with lysate of wt PMNs.  
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emission: 405 nm). The substrates were added to the lysates from 1.5*10
6
 mPMNs at 
room temperature and the measurement was immediately started. The LIX substrate 
(Abz-GVIAATELR-Y(NO2)-D) showed a similar pattern as the MIP-2 substrate (Abz-
GAVVASELR-Y(NO2)-D). It was cleaved by wt lysate, but not by the PR3/NE knockout 
lysate. By contrast, the KC substrate (Abz-GAPIANELR-Y(NO2)-D) could be cleaved 
by lysate of wt and PR3/NE-deficient PMNs, although the cleavage by double knockout 
lysate was diminished.  
4.2 NE escapes inhibition by self-cleavage 
4.2.1 Self-cleavage of NE 
4.2.1.1 Identification of self-cleavage sites 
 After the removal of the propeptide of mNE with enterokinase, the molecular weight 
shift was routinely checked on a SDS-PAGE to ensure complete activation of mNE. In 
doing so it was discovered that in addition to the expected mature form of mNE two 
smaller bands appeared around 20 kDa. Edman sequencing revealed that both bands 
featured the N-terminal sequence of mNE. Thus, at some point during enterokinase 
treatment mNE must have been cleaved in the C-terminal region (Fig 4.11 A). After 
Fig 4.11: Two self-cleavage sites of mNE identified. (A) Purified mNE before (1) (left lane; 5 µg) 
and after the incubation with enterokinase (right lane; 3 µg) was analyzed by SDS-PAGE and 
Coomassie Blue staining. The middle lane contains the prestained protein marker (NEB, P7708). Two 
additional bands (3, 4), besides the mature mNE (2) were detected after EK incubation (right lane). 
Edman sequencing revealed that the bands 3 and 4 started with the mature N-terminus and were 
therefore identified as N-terminal fragments of mNE. (B) Using a small peptide 18% tris-tricine SDS 
gel, the small C-terminal fragments from mNE (5 µg loaded) not visible in panel A were separated 
and subjected to Edman sequencing.  Edman sequencing revealed two cleavage sites at V
178
/N
179
 and 
A
188
/G
189
. Edman sequencing was carried out by Reinhard Mentele (Core facility of MPI 
Biochemistry). 
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running an 18% tris-tricine gel with 5% crosslinking, I was able to separate the two small 
C-terminal fragments. These fragments were blotted on membranes for Edman 
sequencing. Cleavage of mNE occurred between V
178
/N
179 
and
 
A
188
/G
189
, indicating a 
self-cleavage of mNE, as these are elastase-like and not enterokinase cleavage sites (Fig 
4.11 B). In the following intact mNE will be called single chain (sc) and the nicked form 
two chain (tc) mNE. 
4.2.1.2 Self-cleavage of mNE changes its activity 
 Activation of mNE (1-2 mg/ml) was observed over a time course with the addition of 
enterokinase (25-50 µg/ml) as a starting point. At different time points aliquots were 
taken and frozen at -20°C, thus stopping the reaction (Fig 4.12). For SDS-PAGE 2 µg per 
time point of mNE was loaded and160 ng per time point was used for the activity assay. 
The amount of sc-mNE gradually decreased while concentration of tc-mNE increased. 
The tc-mNE represented the most predominant form after 24 hours (Fig 4.12, upper 
panel). This process did not stop, when I added the enterokinase specific D4K-cmk 
inhibitor, verifying our suspicion of self-cleavage as the mechanism generating tc-mNE. 
In addition the activity of mNE at each time point was measured using 
Fig 4.12: Self-cleavage of mNE changes its activity. At time point zero enterokinase (Roche; 
25-50 µg/ml) was added to mNE (1-2 mg/ml). In two experiments enterokinase inhibitor 
D4K-cmk was added after 1.5 hours. Each lane of a 15% SDS polyacrylamide gel stained with 
Coomassie was loaded with 2 µg mNE and 160 ng mNE were used for each activity assay. This 
gel is representative of 5 independent experiments. Activity measurements were always done in 
triplicates with Abz-GAVVASELR-Y(NO2)-D as the substrate. Data shown is mean ± SEM of 
all experiments (n=5). The y-axis shows the activity of mNE with the highest activity of each 
experiment set to 100%. Increasing amount of mNE was nicked over the time, even in the 
presence of enterokinase specific inhibitor. Thus nicking was indeed the result of a self-cleavage 
of mNE. The increase of tc-mNE and decrease of sc-mNE over time was paralleled by a slow, 
gradual decline in  activity.  
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Abz-GAVVASELR-Y(NO2)-D as a substrate. The decrease of sc-NE and increase of tc-
NE correlated with reduced activity over time. 
4.2.2 Does NE inactivate itself via self-cleavage? 
4.2.2.1 Western blot analysis of different mNE variants using a cmk inhibitor 
To further investigate the decline of activity, I used a biotinylated AAPV-cmk inhibitor. 
Only active mNE can covalently react with the inhibitor, thus only active mNE is 
visualized in a western blot (Fig 4.13 A). Murine NE with a concentration of 80 µM was 
incubated with 0.5 mM AAPV-cmk at 37°C for 30 minutes. The six time’s molar excess 
of the inhibitor ensured a complete inhibition of active mNE. I always added the 
AAPV-cmk inhibitor to the mix at the last possible moment, because AAPV-cmk is 
instable in aqueous solutions. A 15% SDS gel was run, where 1 µg was loaded for 
western blot analysis and 8 µg for Coomassie staining. Tc-mNE variant 1 gave a much 
stronger signal than tc-mNE variant 2 in the western blot, although the Coomassie stained 
gel indicated that equal amounts of both variants were present in the sample (Fig 4.13 B). 
Fig 4.13: Western blot analysis of mNE with cmk inhibitor indicates inactivation of mNE 
variant. Biotinylated NE inhibitor AAPV-cmk (0.5 mM) was incubated with 80 µM mNE at 
37°C for 30 min. The biotinylated AAPV-cmk forms a covalent complex with mNE. (A) The 
sample was split and 1 µg mNE was separated by SDS-PAGE (15%) and blotted. After the 
membrane was blocked with 5% (w/v) Non-Fat Dry Milk Blocker (Bio-Rad) the membrane was 
incubated with 0.5 µg/ml avidin-HRP (Invitrogen, 43-4423) at room temperature for one hour. 
(B) 8 µg of the sample was loaded on a 15% SDS-PAGE gel and stained with Coomassie. All 
three variants of mNE were able to react with AAPV-cmk. While Coomassie gel staining 
revealed an equal amount of variant 1 and 2, the signal of variant 1 in western blot analysis is 
much more prominent than that of variant 2. (C) The band labeled as variant 2 actually is derived 
from two different forms of mNE, which are cut at one or two positions. These two forms 
appeared to differ in their activities and most likely account for these discrepancies. 
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The gel showed only two large big N-terminal fragments that were separated from the 
small C-terminal fragments after reduction in the sample buffer. The band called tc-mNE 
variant 2 was derived from a mixture of mNE, which had been nicked once or twice (Fig 
4.13 C).  On the other hand tc-mNE variant 1 exclusively consisted of single cut mNE. A 
different behavior of the single- and double- cut mNE with regards to AAPV-cmk 
inhibition might be a reason for the observed divergence between western blot analysis 
and Comassie staining. 
4.2.2.2 Mass spectrometry analysis of different mNE variants using a cmk inhibitor 
 For further analysis via mass spectrometry, I needed homogenously glycosylated 
tc-mNE. After removal of the glycosylation sites mNE was no longer expressed in 
HEK293EBNA cells (data not shown). Therefore, in cooperation with U-protein 
Fig 4.14: Mass spectrometry analysis of mNE exposed to a cmk inhibitor indicates inactivation 
of the double-nicked mNE variant. Pro-mNE was expressed in HEK293ED (U-Protein Express-BE, 
Utrecht) cells to achieve homogenous glycosylation. Purified pro-mNE (0.35 mg/ml) was incubated 
with enterokinase (NEB; 50 ng/ml) at 37°C over night. (A) The digest was then analysed by mass 
spectrometry performed by E. Weyher  at the MPI of biochemistry. Peak 1 shows the homogenously 
glycosylated mNE (MW: 27.355 kDa). With each self-cleavage the molecular weight increased by the 
size of a water molecule resulting in peak 2 and 3. Clearly in this sample the most prominent peak 
was the single nicked mNE (2), while the peak for intact (1) and double (3) -nicked mNE had roughly 
the same height. (B) AAPA-cmk inhibitor (0.5 mg/ml) was added to the converted mNE from A and 
incubated at 37°C for 30 minutes.  After adding AAPA-cmk inhibitor peak 1 completely disappeared 
and peak 2 was considerably diminished, leaving peak 3 as the most prominent one. As a result I got a 
new peak (4) with a MW of 27.811 kDa, which is the expected weight for the complex between 
single-nicked mNE and AAPA-cmk.  
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Express-BE (Utrecht), tc-mNE was expressed in HEK293ES cells, a N-glycosylation 
deficient cell line, which produces proteins with short homogenous carbohydrate chains 
and the supernatant was sent to us for purification. Purified pro_mNE (0.35 mg/ml) with 
special glycosylation was incubated with enterokinase (NEB; 50 ng/ml) at 37°C over 
night. For inhibition 0.5 mM unbiotinylated AAPA-cmk inhibitor was added to the 
converted mNE and incubated at 37°C for 30 minutes. Mass spectrometry analyses were 
performed by Elisabeth Weyher (core facility of the MPI Biochemistry). Sc-mNE without 
AAPA-cmk inhibitor had a molecular weight of 27.355 kDa as could be seen in peak 1 
(Fig 4.14 A). Each time when mNE cleaved itself, a peptide bond was hydrolyzed and 
one water molecule (18 Da) was gained resulting in peak 2 and 3 with a molecular weight 
of 27.373 or 27.391 kDa respectively. The molecular weight of AAPA-cmk inhibitor is 
475 Da. Because a hydrochloride is released during the AAPA-cmk reaction with mNE, 
the complex has a theoretical weight of 27.794 kDa. Although a complex of this size had 
not been found, peak 1 (sc-mNE) disappeared after the addition of the AAPA-cmk 
indicating that sc-mNE reacted completely with AAPA-cmk (Fig 4.14 B). Peak 2 (once 
cleaved mNE) was significantly reduced and a peak for the mNE-inhibitor complex 
(27.811 kDa), peak 4, appeared. There was still a considerably amount of double nicked 
mNE, while no signal for a protease-inhibitor complex was detected. Altogether, these 
results suggested that double-nicked mNE was inactive. 
4.2.3 Resistant mNE 
The first indication that the cleavage site A
188
/G
189
 might have been more important was 
found in the order of cleavage. Murine pro-mNE (0.5 mg/ml) was incubated with EK 
(50 ng/ml) at room temperature for two hours (Fig 4.15 A). After that AAPA-cmk 
(0.5 mg/ml) was added to stop the self-cleavage of mNE. I loaded 2.5 µg of this 
converted mNE with (Fig 4.15 A, left lane) and without (Fig 4.15 A, right lane) AAPA-
cmk on a 15% SDS gel. I detected tc-mNE variant 1 that resulted from the self-cleavage 
of mNE between A
188
 and G
189
 although I added AAPA-cmk after two hours. 
Furthermore, trypsin cleaved itself at the same topological site as mNE (K
188
/D
189
 
compared to A
188
/G
189
) (Fig 4.15 B). Interestingly, self-cleavage of trypsin at this site 
resulted in a specificity change. This cleavage site is conserved in NE across many 
species (Fig 4.15.C). 
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Taken together the cleavage site A
188
/G
189
 appeared to show functional relevance. That is 
why I mutated Q
187
A
188
 to K
187
G
188
 to prevent the self-cleavage. To test whether this 
mutated mNE was stable I repeated the experiment of chapter 4.2.1.2. Mutated pro-mNE 
(1.1 mg/ml) was incubated with EK (NEB; 78 ng/ml) at 37°C. Enterokinase inhibitor 
D4K-cmk inhibitor was added after two hours. At each time point an aliquot of 2 μg and 
160 ng of mutated mNE was withdrawn for Coomassie blue gel and for an activity assay 
respectively (Fig 4.16). Sc-mNE was almost exclusively seen even after 24 hours. Only 
Fig 4.15: Cleavage between A
188
 and G
189
 might change activity of mNE. (A) To pro-mNE(wt) 
(0.5 mg/ml) 50 ng/ml enterokinase was added and incubated at room temperature for two hours. Then 
AAPA-cmk (0.5 mg/ml) or PBS was added to the digest and incubated at 37°C for 2 hours. The two 
digests (2.5 µg mNE per lane) with (left lane) and without (right lane) AAPA-cmk were loaded on a 
15% Coomassie stained SDS gel. In contrast to tc-mNE var 2, tc-mNE was already detected two 
hours after the conversion of pro-mNE with enterokinase. Tc-mNE var 1 was a product of self-
cleavage at A
188
/G
189
; therefore mNE cleaved itself first at A
188
/G
189
. (B) Trypsin also cleaves itself at 
the same topological site (K
188
/D
189
) similar to mNE at A
188
/G
189
and thereby changes its specificity.  
(C) This cleavage site A
188
/G
189
 is conserved in many NE homologues from many species.  
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Fig 4.16: Mutation of Q
187
A
188
 to K
187
G
188
 prevented self-cleavage of mNE. To test whether the 
mutation was able to abolish self-cleavage, 1.1 mg/ml mutated pro-mNE was activated with EK 
(NEB; 78 ng/ml) at time point zero. After 1.5 hours the D4K-cmk inhibitor was added to inactivate 
enterokinase. For each time point 2 μg mNE was loaded on a 15% SDS polyacrylamide gel for 
subsequent Coomassie staining. An activity assay with 160 ng mNE and Abz-GAVVASELR 
Y(NO2)-D as a substrate was also performed for each time point. This gel is representative of 3 
independent experiments. Activity measurements were always done in triplicates. Data shown is the 
mean +/- SEM of all experiments. No self-cleavage at A
188
/G
189
 was detected and only slight self-
cleavage at V
178
/N
179
 was found. The activity is stable even after 24 hours, thus elimination of self-
cleavage site A
188
/G
189
 was successful. 
 
little cleavage at the second self-cleavage site V
178
/N
179
 was detected. In accordance to 
these findings the activity of the mutated mNE was stable. The activity was measured as 
described in chapter 4.2.1 using Abz-GAVVASELR-Y(NO2)-D as a substrate. Because 
the mutated form of mNE is a stable single-chain form, I suppose that this mutated form 
of mNE represents the natural sc-mNE and will refer to it as such. Data shown were mean 
±SEM of three independent experiments. 
4.2.4 Titration of sc-and tc-mNE  
4.2.4.1 Determination of α1PI concentration 
Direct titration of mNE is not possible at present, because a suitable titration reagent is 
not available. Titrated α1PI was needed for the accurate determination of active mNE. 
Trypsin (Sigma Aldrich) was dissolved in 1 mM HCl and burst titrated as described in 
chapter 3.3.1 (data not shown). A constant concentration of 200 nM trypsin was 
incubated with varying concentrations of α1PI at 37°C for one hour. Residual activity was 
measured with 200 µM Boc-Gln-Gly-Arg-AMC resulting in a typical enzymatic curve 
(Fig 4.17 A). The initial phase of the curve was always linear and the slope was the 
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maximum velocity (vmax) that can be achieved with this amount of active enzyme and 
substrate concentration. The slope was reciprocally proportional to the volume of α1PI 
used, so the total portion of active α1PI could be determined by extrapolation (Fig 4.17 
B). The intersection with the x-axis indicates the amount of α1PI needed to completely 
inhibit trypsin. I always dissolved 1 mg α1PI (Athens research) in 500 µl water. The 
normal concentration was then approximately 4 µM active α1PI.  
Sc- and tc-mNE were then titrated in a similar fashion. In order to work with the same 
sc/tc-mNE ratio every time, I determined the concentration of mNE using absorbance 
measurement or BCA assay and converted wt mNE at a concentration of 0.5 mg/ml. Tc-
mNE was titrated with Boc-APnV-4-chloro-SBzl (Fig 4.18 A) and the active tc-mNE 
concentration was approximately 5-6 µM in this case (Fig 4.18 C). Because the mutation 
protected mNE from self-cleavage, the concentration during activation was not critical. 
Different initial concentrations of sc-mNE were titrated and thus there was not one 
common concentration for titrated sc-mNE. 
  
Fig 4.17: Determination of α1PI concentration. For an accurate determination of α1PI 
concentration, α1PI was titrated with burst titrated trypsin. Increasing α1PI concentrations were 
incubated with 200 nM trypsin at 37°C for one hour. (A) The remaining trypsin activity was measured 
using 200 µM Boc-Gln-Gly-Arg-AMC as a substrate (excitation: 350 nm, emission: 450 nm). The 
fluorescence is given in relative fluorescence units (RFU). The graph shown is an example for the 
described reaction. 200 nM trypsin was incubated with 64 nM α1PI at 37°C for one hour. (B) The 
slope of the linear part of the curve  in A is the maximum velocity and is directly correlated with the 
concentration of active trypsin. The amount of α1PI was then plotted against the slope to extrapolate 
the volume of α1PI needed to inhibit trypsin completely. Graphs shown are typical examples for 
reactions described.  
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4.2.5 Testing of different substrates  
Testing sc- and tc-mNE towards several substrates, I observed differences between these 
two forms. I chose the two most interesting substrates and analyzed them in detail. Both 
substrates represent the reactive center loop sequence of two serpins, which are natural 
serine protease inhibitors.  
Fig 4.18: Titration of sc- and tc-mNE. Determination of the concentration of active sc- and tc-mNE 
was done similarly as for α1PI. In this case the concentration of sc- or tc-mNE respectively was held 
constant and the α1PI concentration was varied. (A) The remaining activity of sc-mNE was measured 
with 0.5 mM AAPV-pNA The negative control was only substrate and buffer (grey dots). (B) The 
remaining activity of tc-mNE was measured with 1 mM APnV-Sbzl and 0.5 mM DTNB. The 
negative control was only substrate and buffer (grey dots). As an example the graph of sc-mNE and 
tc-mNE without α1PI are shown in A and B. (C, D) Plotting the concentration of α1PI against relative 
vmax (slope of linear section in the curves) results in a linear regression line, which is extrapolated by 
using GraphPad Prism. The x-intercept showed the concentration needed to completely inactivate 
mNE. Because α1PI and mNE react in a 1:1 ratio, the x-intercept equals the concentration of active 
mNE used. From these values, the concentration of the stock solution of mNE can then be calculated. 
Graphs shown are examples for described reactions.  
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I used 231 nM tc-mNE and 23 nM sc-mNE and varied the substrate concentration 
between one to 80 µM. Since RFU was proportional to the substrate concentration, 
relative fluorescence units (RFU) were converted to substrate concentration. Fitting the 
subsequent Michaelis-Menten curve (Eq. 3) (Fig 4.19 A, B) with GraphPad Prism 
revealed that RCL of α1PI (Mca-GEAIPMSIPPEVK(Dnp)-rr) was a eight times better 
substrate for sc-mNE than tc-mNE with Kcat/KM=14.9 (±0.7)*10
+4
 M
-1
s
-1
 for sc-mNE and 
Fig 4.19: Activities of sc- and tc-mNE towards two different substrates. (A) Substrate 
concentration was varied (1-80 µM), while protease concentration was kept constant (sc-mNE=0.23 
uM and tc-mNE=2.3 uM). Plotting substrate concentration against the relative maximum velocity vmax 
(slope of linear section in the graphs) renders a graph that was fitted to Michaelis-Menten kinetics 
(Eq. 4) using GraphPad Prism. Kcat and KM for sc- and tc-mNE can be calculated using Eq. 3, 4. (A) 
The reactivity of sc- (left panel) and tc-mNE (right panel) towards the α1PI-substrate (Mca-
GEAIPMSIPPEVK(Dnp)-rr) was determined as described above. (B) The reactivity of sc- (left panel) 
and tc-mNE (right panel) towards the MNEI-substrate (Mca-GIATFCMLPEQ(Dnp)-rr) was 
determined as described above. Each experiment was done in triplicate and data shown is mean +/- 
SEM (n=3). The conditions for the measurement of the fluorescence: excitation: 320 nm, emission: 
405 nm. The results are listed in Tab 4.1. 
Results 
- 56 - 
 
1.8 (±0.7)*10
+4
 M
-1
s
-1
 for tc-mNE (Tab). Responsible for the difference is the turnover 
number kcat, which is more than eleven times better for sc-mNE (kcat=3.9 (±1.7) s
-1
) than 
tc-mNE (kcat=0.35 (±0.03) s
-1
). In contrast, there was almost no difference between the 
Michaelis constant KM of sc-mNE (KM=27.8(±7)) and tc-mNE (KM=20.9(±6)). Constants 
calculated here, are mean ±SEM from three independent experiments. 
 
By contrast, the substrate Mca-GIATFCMLMPEQ-(Dnp)-rr representing the RCL of 
MNEI was cleaved by sc- and tc-mNE almost equally well with kcat/KM of 4 (±2)*10
+4
 M
-
1
s
-1
 and 2 (±2)*10
+4
 M
-1
s
-1
, respectively (Fig 4.19 C, D). Similar to the RCL of MNEI, 
kcat for sc-mNE (0.99(±0.71)) was better than for tc-mNE (0.02 (±0.01), but the almost 
ten times lower KM of tc-mNE (2(±2)) compared to sc-mNE (21(±1)) compensated this to 
a high degree. Constants calculated here, were mean ±SEM from three independent 
experiments. 
4.2.6 Inhibitors 
Until now, I only looked at the ability of mNE to cleave the RCL sequence of SERPINs. 
Cleavage of RCL is necessary, but not enough to inhibit mNE and to form mNE-inhibitor 
complexes. First, I ensured that sc- and tc-mNE could still form complexes with α1PI and 
were still irreversible inhibited. To demonstrate this, 6 µg sc-mNE and tc-mNE were 
incubated with 15.6 µg α1PI at 37°C and the reaction was interrupted at different time 
points by taking aliquots, containing 1 µg of mNE and 2.6 µg α1PI, and boiling them 
immediately with reducing sample buffer at 95°C (Fig 4.20 A, B). The ester-bond 
between mNE and α1PI was stable even after reduction, thus the mNE- α1PI complexes 
could be identified in a reducing SDS gel by the shift in the molecular weight. Sc-mNE 
has a molecular weight of 25 kDa and α1PI one of 52 kDa. After formation of the ester 
bond a small C-terminal portion of α1PI (4 kDa) was lost. Therefore the sc-mNE-α1PI 
complex was 73 kDa. Within seconds sc-mNE had completely reacted with α1PI, as 
substrate  
KM 
[µM] 
kcat 
[s
-1
] 
kcat/KM
 
[M
-1
s
-1
] 
substrate 1 
Mca-GEAIPMSIPPEVK(Dnp)-rr 
sc-mNE 27.8(±7) 3.92 (±1.73) 14. 9(±0.7)*104 
tc-mNE 20.9(±6) 0.35(±0.03) 1.8(±0.7)*104 
substrate 2 
Mca-GIATFCMLMPEQ-(Dnp)-rr 
sc-mNE 21(±1) 0.99(±0.71) 4 (±2)*104
 
tc-mNE 2 (±2) 0.02(±0.01) 2 (±2)*104
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could be seen by the disappearance of sc-mNE and the emerging of th sc-mNE-α1PI 
complex at 73 kDa. Identification of the tc-mNE-α1PI complex was somewhat more 
difficult. The ester bond between mNE and α1PI was between the Ser195 from mNE and 
Met358 from α1PI. After reduction the tc-mNE fell apart and only its C-terminal part 
with 7 kDa remained bound to α1PI. The tc-mNE- α1PI complex had therefore a 
molecular weight of 55 kDa and run slightly above α1PI on a reducing SDS gel. After 30 
seconds the first complexes were seen. But even after 20 min the reaction was not 
finished yet. 
 Although complex formation between tc-mNE and α1PI was considerably slower, α1PI 
could still inhibit tc-mNE irreversibly. As described in chapter 3.3.3 kobs was determined 
by adding mNE to mixes of different α1PI amounts (0-0.73 µM) and a constant substrate 
amount (Mca-GEAIPTSIPPEVK(Dnp)-rr; 152.12 µM). The resulting competition between 
substrate and α1PI gave characteristic curves (Fig 4.21 A, B) that were fitted to Eq. 8 
using GrapPad Prism. All experiments were done in duplicates and repeated thrice. The 
Fig 4.20: Complexation between the tc-mNE and α1P is impaired. (A) Sc-mNE (black square; 
6 µg) was incubated with 15.6 µg α1PI at 37°C. Aliquots with 1 µg sc-mNE and 2.6 µg α1PI were 
taken at different time points and immediately boiled in reducing sample buffer at 95°C. Sc-mNE 
disappeared within seconds. At the same time, a band at approximately 73 kDa appeared. This 
position corresponds to the MW of the sc-mNE- α1PI complex, thus sc-mNE forms a complex 
with α1PI during the first 30 seconds. (B) The experiment of A was repeated with tc-mNE (black 
triangle). In contrast to sc-mNE, tc-mNE-α1PI complex formed much slower. Since only the 
C-terminus of tc-mNE remains attached to the complex after reduction, the tc-mNE-α1PI complex 
is much smaller and runs only slightly above natural α1PI. Even after 20 minutes I saw a reduction 
of the α1PI band and an increase of the tc-mNE-α1PI band, indicating that the reaction was still not 
finished at that time point. Gels shown are representative of three independent experiments. 
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Fig 4.21: Tc-mNE inhibition with α1PI impaired. (A) Sc-mNE (10 nM) is given to a mix of 
152.12 µM substrate and varying α1PI concentrations (0-0.73 µM). The y-axis shows the fluorescence 
in relative fluorescence units (RFU) (excitation: 320 nm, emission: 405 nm). The subsequent curves 
were fitted with GraphPad Prism to Eq. 8. Data shown are examples with ± SEM and n=2. The graph 
is an example and 0.18 µM α1PI was used in this experiment. (B) The experiments in A were 
repeated in B with the same conditions by substituting sc-mNE with tc-mNE. As an example a graph 
with 0.12 µM α1PI is shown. (C,D) The resulting kobs values were than plotted against α1PI 
concentration to determine Kass. The resulting graph is fitted to Eq. 9 using GraphPad Prism. Data 
shown is mean ± SEM of all experiments (n=3). Nicking of mNE resulted in an 15 times slower 
inhibition of α1PI (Kass(sc-mNE)= 4.6(±0.5)*10
+6
 M
-1
s
-
1 and Kass(tc-mNE)= 3.1(±1.4)*10
+5
 M
-1
s
-1
). 
 
calculated kobs values were then plotted against the corresponding α1PI concentration 
(Fig 4.21 C, D) and fitted to fit Eq. 8 in GraphPad Prism. Kass was the constant that 
describes the association rate between mNE and α1PI to form an initial encounter 
complex and was in this case the speed limiting factor. While sc-mNE had a Kass of 4.6 
(±0.5)*10
+6 
M
-1
s
-1
, tc-mNE had a Kass of 3.1(±1.4)*10
+5
 M
-1
s
-1 
with α1PI, meaning sc-
mNE was 15 times faster inhibited by α1PI than tc-mNE. Constants calculated here, were 
mean ±SEM from three independent experiments. 
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Fig 4.22: Inhibition of sc- and tc-mNE by Z-α1PI. To estimate the concentration of active Z-α1PI 
sc-mNE was incubated with varying amounts of Z-α1PI at room temperature for 30 minutes. The 
residual activity was measured by adding 20 µM substrate (MCA-GEAIPTSIPPEVK(Dnp)-rr). The 
amount of Z-α1PI was plotted against the slope. The x-axis intercept is the minimal amount necessary 
to inhibit 100 nM sc-mNE completely. This calculated amount of Z-α1PI  was incubated with 100 nM 
sc- (white squares) and tc-mNE (white triangles) at room temperature for 5 minutes before adding 
substrate to the reaction. While sc-mNE was completely inhibited after 5 minutes, tc-mNE still 
showed some activity. For positive control sc- (black squares) or tc-mNE (black triangles) were 
incubated with 20 µM substrate. Data ±SEM are representative of three experiments. 
 
 
4.2.6.1 Z-α1PI 
Z- α1PI was expressed in HEK293 cells and purified via Ni-column (data not shown). 
The sequence is listed in the appendix (8.2.5). As Z-α1PI is prone to polymerization, Z- 
α1PI was only stable at 4°C for one day. Experiments had to be performed on the same 
day and titration of active Z- α1PI was not possible. To estimate the concentration, 
different amounts of Z- α1PI were incubated with 100 nM sc-mNE at room temperature 
for 30 minutes. Thereafter 20 µM substrate (MCA-GEAIPTSIPPEVK(Dnp)-rr) was 
added to measure residual sc-mNE activity. The minimal amount of Z-α1PI needed to 
inhibit sc-mNE completely, was then incubated with 100 nM sc- or tc-mNE at room 
temperature for 5 minutes. By adding 20 µM substrate (MCA-GEAIPTSIPPEVK(Dnp)-
rr)  the remaining active tc-mNE was measured. In contrast to sc-mNE, tc-mNE was still 
active. Therefore tc-mNE was poorly inhibited by Z- α1PI compared to the sc-mNE. This 
experiment was repeated three times with different batches of Z- α1PI. 
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4.2.6.2 Small molecule inhibitor 
Besides the natural inhibitor α1PI I also tested whether inhibition by AZ111177, a small 
molecule inhibitor designed for therapeutic use, was also affected. The inhibitor was 
kindly provided by Astra Zeneca along with the information that the mechanism of 
inhibition is reversible. For reversible inhibition the dissociation constant KD was the 
negative reciprocal value of Kass, and was used to compare inhibition strength. To this 
purpose, Michaelis-Menten curves with different AZ111177 concentration were 
determined (Fig 4.23). GraphPad Prism was used to calculate Ki from these by fitting 
these graphs to Eq. 6. All experiments were done in duplicates and repeated thrice. The 
Ki of sc-mNE is 1.7 (±2) µM. Compared to this, Ki of tc-mNE is 17 times worse (Ki of tc-
mNE= 27.9 (±27) µM). Constants calculated here, were mean ±SEM from three 
Fig 4.23: Inhibition of tc-mNE by AZ111177 was worse than that of sc-mNE. (A) Relative 
maximum vmax (slope of linear section in the curves) of sc-mNE (23.81 nM) with varying substrate 
concentration (MCA-GEAIPTSIPPEVK(Dnp)-rr; 1-80 µM) was plotted against substrate 
concentrations. The graph is fitted to the Michaelis-Menten equation Eq. 4. This procedure is repeated 
with sc-mNE that was incubated with different AZ111177 concentrations (20-800 nM) at 37°C for one 
hour beforehand. For the graph shown here 20 nM AZ111177 was used.  (B) The experiment 
described in A was repeated with tc-mNE. As an example a graph with 2 µM AZ111177 is shown. 
Data shown are representative for three independent experiments. Filled symbols represent graphs of 
uninhibited sc- (black squares) or tc-mNE (black triangle). Hollow symbols show a graph in the 
presence of the inhibitor. All experiments were done in duplicates and repeated thrice. The graphs 
were fitted to Eq. 6 with GraphPad Prism. With Ki (sc-mNE)= 1.712(±2) µM and Ki (tc-mNE)= 
27.922 (±27) µM, inhibition of tc-mNE is 17 times worse than that of sc-mNE by AZ111177. 
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independent experiments. 
4.2.7 Natural occurrence of tc-mNE  
To adress the question, whether the tc-mNE form also occurs in-vivo, I analyzed the 
PMNs as NE was stored there in a large quantity  there. I investigated murine as well as 
human PMNs. Murine PMNs were isolated from bone marrow cells using a percoll 
gradient. Whole PMNs lysate from 1*10
6
 mPMNs was separated on 15% reducing SDS 
gel and blotted (Fig. 4.15 A). The mebrane was incubated with 1µg/ml anti-hNE antibody 
Fig 4.24: Tc-NE was found in PMNs. Both human and murine PMNs were investigated for the 
existence of tc-NE. (A) Lysate of 1*10
6
 mPMNs was separated by SDS-PAGE and after blotting the 
membrane was incubated with 1 µg/ml anti-hNE antibody (Abcam; ab68672), which cross reacts with 
mNE, at 4°C over night.. The second antibody HRP-coupled anti-rabbit antibody was 1:5000 diluted 
and incubated at room temperature for 1 hour. To demonstrate the specificity of the anti-hNE 
antibody for mNE, lysate of PR3/NE deficient PMNs was loaded on the same gel. In wt hPMNs two 
bands corresponding to sc- and tc-mNE respectively could be found, while no bands were visible in 
the knockout lysate. The membrane was incubated in stripping buffer (200 mM glycine, 0.1% SDS, 
pH 2.2) to remove the antibodies at room temperature for 30 minutes. The membrane was incubated 
with anti-human haptoglobin antibody (Dako; 1:1000 diluted) at 4°C over night. Detection of 
haptoglobin ensured that I had compared equal amounts of wt (right lane) and PR3/NE deficient (left 
lane) PMN lysate. All experiments were repeated thrice. (B) Lysate of 3*10
6
 hPMNs was first 
inhibited with 20 nmol biotinylated AAPV-cmk inhibitor, which reacts covalently with hNE. To 
isolated hNE, I first immunoprecipitated it with 4.4 µg anti-hNE (QED; 13203) and subsequently 
purified the hNE-antibody complexes with the help of 30 µl Protein G-dynabeads (Invitrogen). After 
boiling the beads with loading buffer and performing a SDS-PAGE the samples were blotted on a 
membrane. HRP-coupled streptavidin (Millipore; OR03L) was added in a 1:1000 dilution and 
incubated at room temperature for 1 hour. The co-migration of the two bands with a MW of about 20 
kDa from control hNE (Elastin products; 500 ng) and the PMNs lysate strongly suggests that the band 
observed in neutrophil lysates is identical with that obtained by self-cleavage. All experiments were 
repeated thrice.  
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(Abcam; ab68672) that was crossreacting with mNE. I was able to identify sc- and tc-
mNE. As a control lysate from 1*10
6
 PR3/NE deficient PMNs were loaded on the same 
gel. No bands were detected at the appropiate height. To ensure that an equal amount of 
wt and PR3/NE knockout lysate was compared, the membrane was stripped with 
stripping buffer (200 nM glycine, 0.1% SDS, pH 2.2) at room temperature for 1 hour. 
Then the mebrane was incubated with an anti-haptoglobin antibody Dako; 1:1000 
dilution).  
For human PMNs I had to change my protocol as there was no antibody available, which 
was sensitive enough to detect tc-mNE by western blot. Therefore, lysate of 3*10
6
 
hPMNs was first covalently inhibited with 20 nmol biotinylated AAPV-cmk inhibitor, 
before an immunoprecipitation with 4.4 µg anti-hNE antibody (QED; 13203 ) was 
performed. The Protein G dynabeads (Invitrogen; 30 µl), which were used to capture the 
hNE-antibody complexes, were boiled at 95°C with sample buffer and analyzed on a 15% 
SDS gel. After blotting the samples on a membrane, the mebrane was incubated with 
1:1000 diluted HRP-coupled streptavidin (Millipore; OR03L). As only active mNE could 
react with AAPA-cmk inhibitor, only active hNE was detected with this method. 
Commercially availabe hNE (Elastin products) was loaded as a control on the gel (500 ng 
per lane). The bands of the immunoprecipitated hPMNs corresponded to the bands that 
were also seen in the control hNE. Both sc- and tc-hNE were found in hPMNs. All 
experiments were repeated three times. 
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5 Discussion 
In recent years, emerging evidence revealed a regulatory role of NSPs in immune defense 
reactions and not only a merely destructive role. Besides the degradation of pathogens 
and ECM, extracellular NSPs were specifically involved in controlling and directing the 
inflammatory process (Pham, 2008). In this study, the role of extracellular PR3 and NE 
during inflammation was investigated in more detail. I focused especially on the impact 
of these NSPs on chemokine regulation. To this end several methods and tools were 
developed with the final goal to investigate the processing of chemokines via NSPs in 
vivo. In the course of this research, I also found a modified form of NE, which was 
further analyzed. By nicking itself, NE could change specificity and could escape from 
efficient inhibition by α1PI. 
5.1 NSP regulate inflammation by processing chemokines 
PR3/NE deficient mice showed an attenuated response towards IC-mediated 
inflammation. Not only were less neutrophils recruited to the inflammation site, but also 
oxidative burst reaction was diminished (Kessenbrock et al., 2008). The degradation of 
progranulin, an anti-inflammatory protein, has been identified as one target of PR3 and 
NE. The prolonged bioactivity of intact progranulin in the absence of PR3 and NE, was in 
part responsible for the impaired IC-mediated inflammatory reaction (Kessenbrock et al., 
2008). Of course, progranulin was hardly the only protein these proteases were 
encountering. Chemokines are key players for leukocyte recruitment and also control 
inflammation. Worthy of note here was that chemokines have been found in different 
isoforms in vivo. For IL-8 at least ten different isoforms could be identified (Proost et al., 
2008). Trimming of the N-terminus in various ways was detected, which was likely 
caused by proteolytic cleavage. At present it is unknown, which protease is responsible 
for the processing of IL-8. Based on in vitro studies several candidates, e.g. hPR3, had 
been proposed (Mortier et al., 2008; Padrines et al., 1994; Wolf et al., 2008).  
As proteolytic processing is most likely implicated in the generation of isoforms of 
chemokines, chemokines are plausible substrate candidates for PR3 and NE (Mortier et 
al., 2008; Wolf et al., 2008). Moreover neutrophils have been reported to be a source of 
chemokines (Kasama et al., 2005; Scapini et al., 2000). Interestingly, both IL-8 and 
MIP-2, members of the family of CXC ELR
+
 chemokines, belonged to this group of 
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neutrophil-derived chemokines (Scapini et al., 2000). Cathepsin G was able to influence 
the MIP-2 levels in a non-proteolytically function (Raptis et al., 2005). I addressed the 
question of whether NSPs also influence MIP-2 in a proteolytic way. I could indeed show 
that mPR3 as well as mNE was able to cleave MIP-2 after Ala
4
 in vitro. In an under-
agarose assay this shortened MIP-2 was able to attract more neutrophils than intact MIP-
2. This finding is in accordance to  the oberservation that IL-8 was also cleaved by hPR3 
in vitro and this isoform was also more chemotactic than the unprocessed precursor 
(Nourshargh et al., 1992; Padrines et al., 1994).  
My new observation supported the view that both mPR3 and mNE play a pro-
inflammatory role in antibacterial defense responses (Kessenbrock et al., 2011). A 
substrate featuring the N-terminal sequence of MIP-2 was incubated with lysate of wt or 
PR3/NE deficient PMNs. As this substrate was only cleaved by the lysate of wt but not by 
that of PR3/NE deficient PMNs, mPR3 and mNE are the only proteases among many 
other endoproteases present in PMNs that are able to process MIP-2. In contrast to our 
substrate, the MIP-2 N-terminus was not protected. Hence, exopeptidases could trim the 
N-terminus and could still be involved in MIP-2 processing. For a better understanding, 
MIP-2 was incubated with TNF-α primed mPMNs. In this experiment, all proteases 
including exopeptidases of mPMNs were competing with each other for MIP-2. After 
immunoprecipitation, I blotted MIP-2 on a membrane for Edman sequencing. Incubation 
with wt, but not with PR3/NE knockout mPMNs yielded N-terminally processed MIP-
2(5-73). Full length MIP-2 was not completely converted and was identified in both 
samples. This experiment confirmed our previous finding with the MIP-2 substrate. PR3 
and NE seemed to be the only proteases in mPMNs that could process MIP-2. 
I tried to understand the impact of N-terminal trimming on its chemotactic activity. For 
this purpose I produced not only intact and processed MIP-2, but also N-terminally and 
C-terminally elongated versions. Ch_MIP-2 was chemotactically inert, but could be 
activated by mPR3 or mNE cleavage. This switch from inactive to active could be 
demonstrated more easily than the conversion of MIP-2(1-73) to MIP-2(5-73), which 
resulted only in an enhancement of the chemotactic activity. As the N-terminal extension 
of MIP-2(1-73) was rather large, I first had to test whether mPR3 and mNE still 
maintained the ability to cleave Ch_MIP-2. This was indeed the case and I therefore 
proceeded with the next experiment.  
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Binding of chemotactically active MIP-2 triggered receptor internalization. Wild type 
mPMNs isolated from the bone marrow were incubated with all four variants of MIP-2. 
Then remaining CXCR2 receptors on the surface were measured and compared with the 
amount of CXCR2 receptors on untreated mPMNs. Since binding to the receptor was a 
prerequisite to induce its internalization and responses in PMNs, it was a measure for the 
strength of MIP-2 binding. I expected that the more chemotactic forms of MIP-2 would 
bind better to CXCR2 resulting in a stronger reduction of CXCR2 on the surface. 
Surprisingly, all isoforms induced a similar reduction of CXCR2. Even Ch_MIP2 was 
able to bind to CXCR2, although this isoform was supposed to be chemotactically 
neutral. This unexpected result has been probably obtained, because wt PMNs were used 
in this experiment. Wt mPMNs carry mPR3 and mNE. Due to the purification on a 
percoll gradient these mPMNs most likely were partially activated. Some active mPR3 
and mNE were active on the surface of mPMNs and might have converted Ch_MIP-2 to 
MIP-2(5-73). MIP-2(5-73) in turn could bind to CXCR2 and thereby triggered receptor 
internalization. To verify my hypothesis, I used PR3/NE deficient mPMNs. As these 
knockout mPMNs did not express mPR3 and mNE anymore, they should be unable to 
convert Ch_MIP2 and hence CXCR2 should remain on the surface. In line with my 
prediction CXCR2 on PR3/NE deficient mPMNs did not get internalized after incubation 
with Ch_MIP-2, while the other three isoforms still induced receptor internalization. With 
this experiment, I was able to demonstrate that active mPR3 and mNE is on the surface of 
activated wt mPMNs. This finding is remarkable, because mPR3 and mNE were normally 
stored in the primary granules, which were the type of granules to be discharged last 
(Borregaard et al., 2007).  
I did not detect a difference between MIP-2(1-73), MIP-2(5-73) and MIP-2_Ru. The 
chemotactic strength was either not correlated to the binding affinity to the receptor or I 
used too much MIP-2, and so saturated the receptor with all variants. I tried to lower the 
amount of MIP-2, but still could not see a difference. I think the concentration of MIP-2 
was not measured accurately enough to notice small differences in bioactivity.  
MIP-2 is not the only CXC ELR
+
 chemokine; there is also KC (CXCL1), DCIP-1 
(CXCL3) and LIX (CXCL5). As the N-terminal sequence showed suitable cleavage sites 
for mPR3 and mNE, I tested whether one of the other chemokines could also be 
processed. DCIP-1 had actually the same N-terminal sequence as MIP-2 and thus could 
definitely be processed by mPR3 and mNE. As done in the case of MIP-2, substrates 
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featuring the N-terminal sequence of these chemokines were ordered. Lysates of wt 
mPMNs could cleave all three sequences, implying that all chemokines could be 
processed by neutrophil proteases. After incubating the LIX- substrate with lysates of 
PR3/NE knockout mPMNs, I did not observe any cleavage. The only endoproteases of 
mPMNs capable of cleaving LIX were found to be mPR3 and mNE. But the substrate did 
not feature the whole N-terminus of LIX as LIX had a longer N-terminus than the other 
chemokines. So other proteases could still cleave the remaining N-terminus not covered 
by the substrate. In fact, it has been reported that MMP-8 could process LIX after Ser
4
 
and that this cleavage enhanced its chemotactic activity (Tester et al., 2007). LIX could 
be further shortened by mPR3 and was thus an interesting target for mNE. Besides that 
the longer N-terminus protected LIX from exopeptidase trimming. The KC-derived 
substrate, however, was still cleaved by the lysate of PR3/NE deficient mPMNs. 
Evidently, some other endoproteases could also cleave KC.  
In conclusion, mPR3 and mNE could process the N-terminus of some CXC ELR
+
 
chemokines. In the case of MIP-2 this led to an enhancement of the chemotactic 
properties. Lysate, supernatant and mPMNs were able to cleave MIP-2 and to induce 
CXCR2 receptor internalization. Of course in vivo evidence for these processing events 
are needed. Detecting MIP-2 was very hard as the concentration range is normally 
between 100-1000 pM. To this end I have set up a cooperation with David Meierhoff 
(MPI Berlin). Targeted mass spectrometry was very sensitive and the detection limit of 
MIP-2 was down to 1 fM. Up to now, we have established a working protocol. At the 
moment, we are analyzing biological samples from different inflammatory mouse models 
to see how chemokines are modified at the N-terminus in vivo. 
5.2 NE escapes inhibition by self-cleavage 
During the studies of NE, the appearance of two unexplained bands after enterokinase 
conversion attracted my interest. Further analysis revealed these as fragments of NE. 
Since only enterokinase and mNE were present in the sample, one of these two proteases 
came into question. The cleavage sites V
178
/N
179
 and A
188
/G
189
 pointed to mNE, as mNE 
was said  to prefer small aliphatic residues (Hedstrom, 2002), whereas enterokinase 
cleaved after D4K.  NE was still cleaved, despite the addition of an enterokinase specific 
inhibitor (D4K-cmk). This was the final proof for the self-cleavage of mNE. There were 
several possible functions for the self-cleavage. As already mentioned, self-cleavage of 
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trypsin was an important mechanism for the termination of its activity and could lead to 
either inactivation or even a change in specificity (Kay and Kassell, 1971; Whitcomb et 
al., 1996). Failure of this self-limiting mechanism actually resulted in a disease, called 
pancreatitis (Simon et al., 2002; Whitcomb et al., 1996). The question was therefore, 
whether these possibilities also applied to mNE. Especially the cleavage of the A
188
/G
189
 
peptide bond held great promise of uncovering new elastase properties. Not only was this 
site conserved throughout many species homologues, but also matched a self-cleavage 
site in trypsin at a topologically equivalent position (K
188
/D
189
). This cleavage site was 
located on a loop, which shaped the S1 pocket (Specificity et al., 1989). It has been 
shown that residue 189 is very important for substrate specificity. For example the Asp
189
 
in trypsin was responsible for its preference to cleave after Arg or Lys (Hedstrom, 2002). 
Cleavage at this position was therefore of significant relevance for the activity of mNE. 
Moreover, this site A
188
/G
189
 seemed to be the highly favored cleavage site in mNE, as it 
was always cleaved first. Once cleaved, a small portion of mNE was further processed at 
a second self-cleavage site. This suggests that the prime cleavage at A
188
/G
189
 made the 
other minor cleavage site V
178
N
179
 more accessible to mNE.  
 
Fig 5.1: Autocleavage of human NE. Human NE is shown in the standard orientation according 
to Wolfram Bode. α-helices in red, β-sheets in blue and turns are painted in green. The catalytic 
triad residues, His
57
, Asp
102
 and Ser
195
, are depicted with their respective side chains.  Human NE 
cleaved itself between Ala
188
 and Gly
189
. As this loops is located on a loop that is essential for the 
shaping of the S1 pocket, a cleavage at this site is expected to have an impact on the substrate 
specificity of hNE. The raw data for the structure of hNE was obtained from the RCSB protein 
data bank (file number: 3Q76) and modified using the program Viewer Lite 5.0 (Accelrys Inc, 
San Diego). 
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Initial experiments on the activity of nicked mNE showed that it was moderately 
diminished but not completely destroyed. Thus, the primary purpose of this self-cleavage 
site was not the inactivation of mNE, although we found some hints that the double-
cleaved mNE might be inactive. The first clue for this conclusion was found in an 
experiment, where a mixture of sc- and tc-mNE was incubated with biotinylated AAPV-
inhibitor to visualize active mNE (Fig4.12). If all of the mNE retained its activity, the 
signals of the western blot and Coomassie staining should be the same. As the lower band 
was clearly weaker in the western blot compared to the amount of protein in this band, I 
suggested that the tc-mNE did not react with the inhibitor. As the lower band contained 
both a single-nicked mNE (cleaved between V
178 
and N
179
) and a double-nicked mNE, a 
plausible interpretation was the loss of activity after the double-cut. But at this point in 
time, I had not shown the existence of double-nicked mNE. Every time when a peptide 
bond was hydrolyzed in mNE, a water molecule of 18 Da was added to the mNE 
molecule. As mass spectrometry was sensitive enough to actually detect the gained water 
molecule, NE was analyzed by mass spectrometry. Indeed, intact, single- and double-
nicked mNE could be clearly differentiated. As expected, the peak for sc-mNE 
disappeared after the addition of the AAPV-cmk inhibitor. To my surprise, a small peak 
of single-cut mNE remained. But the highest unreactive peak was without a doubt the 
double-nicked mNE, which did not react with the inhibitor. I expected two new peaks for 
mNE-cmk complexes, but only found one. This peak was identified as the single-nicked 
mNE-cmk complex, so the intact mNE-cmk complex was missing. Altogether, I could 
show that double nicked mNE exist. And all the evidence indicated that double-nicked 
mNE was inactive. 
Double-cutting of mNE occurred only to a small degree. Up to eight hours of incubation 
the lion’s share of mNE modification was the single-nicked form, cleaved at A
188
/G
189
. 
Cleavage of trypsin at K
188
/D
189
, the topological precedent of the A
188
/G
189
 cleavage in 
mNE, resulted in a change of specificity (Keil-Dlouhá et al., 1971; Smith and Shaw, 
1969). Trypsin gained a chymotrypsin-like specificity (Keil-Dlouhá et al., 1971). 
Although, profiling of protease specificity with tandem mass spectrometry by Oliver 
Schilling did not reveal a drastic change of specificity in tc-mNE, I was nevertheless able 
to detect a change in substrate preferences. After testing several substrates, I recognized 
that tc-mNE had a narrower range of substrate specificity. While the tc-mNE activity was 
almost the same for certain substrates, it worsened considerably for others. A substrate 
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featuring the RCL of MNEI (Mca-GIATFCMLMPEQ-(Dnp)-rr) was a good example to 
illustrate this finding. The KM/kcat was in the same order for sc- and tc-mNE. By contrast 
the substrate with the RCL of α1PI (Mca-GEAIPMSIPPEVK(Dnp)-rr) was truly 
interesting. This sequence was a much worse substrate for tc-mNE than for sc-mNE. 
Because cleavage of the RCL was an absolute prerequisite for irreversible inhibition of 
mNE by α1PI, tc-NE appeared to be poorly inhibited by α1PI. As α1PI was demonstrated 
to be the most important inhibitor for mNE in our body, it was an exciting finding (Travis 
and Salvesen, 1983). NE was a protease with a very broad cleavage range. Why would 
this enzyme only cleave itself to reduce its substrate spectrum? One hypothesis for the 
function of this self-limiting substrate specificity is the following. Through self-inflicted 
restriction, NE could escape its inhibition by α1PI and could act longer on certain 
substrates. This would enable NE to focus its activity on a narrow circle of substrates. An 
ideal substrate for a long lasting activity should have an amplifying and regulatory 
function, as this would leverage the prolonged NE activity further. At present our 
knowledge about the most relevant regulatory substrates of NE is very limited, because 
most previous studies focused on the destructive nature of NE. Hence, I was unable to 
evaluate a suitable substrate in support of my hypothesis. Although I was unable to 
substantiate my idea along these lines, there was still the interesting observation of an 
impaired inhibition of tc-mNE by α1PI. The tc-mNE could not only enhance 
inflammation by regulating biological mediators, but could also have a longer action time 
to generate damage. In the introduction I already mentioned that patients with the Z-allel 
had reduced α1PI plasma levels. Low plasma levels and the impaired NE inhibition were 
blamed for the development of lung emphysema (Garver et al., 1986; Lomas et al., 1993). 
Because the Z-variant of α1PI tended to aggregate, it was speculated that these inclusion 
bodies themselves were responsible for emphysema development (Carrell et al., 1994; 
Gooptu et al., 2009). But it has also been reported, that patients that completely lacked 
α1PI in their plasma and are therefore unable to produce aggregates, still developed 
emphysema (Garver et al., 1986; Satoh et al., 1988). Hence impaired inhibition of 
tc-mNE by α1PI and prolonged activity appeared to be a pathogenic factor for 
emphysema. 
First, I had to determine, whether tc-mNE was indeed less well inhibited by α1PI than 
sc-mNE. Although α1PI still formed complexes with tc-mNE, these complexes were 
formed more slowly. While sc-mNE reacted with α1PI within seconds, the reaction of 
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tc-mNE with α1PI took around 30 minutes. Not only complex formation was 
compromised, but also formation of the encounter complex was worse. The reaction of 
α1PI with mNE was described in two steps: First an encounter complex had to be 
assembled. Up to this time point the reaction was still reversible (Gettins, 2002; Travis 
and Salvesen, 1983). In the second step the enzyme attacked the RCL of α1PI and mNE 
and α1PI formed a covalent acyl-enzyme complex (Gettins, 2002; Travis and Salvesen, 
1983). In a substrate reaction the substrate would be freed from the enzyme after 
hydrolysis of the acyl bond. But with α1PI a conformational change of α1PI distorted the 
active center of mNE, so the catalytical function of mNE was lost and mNE was 
irrevocably bound to α1PI (Gettins, 2002; Huntington, 2011; Travis and Salvesen, 1983). 
Here, the formation of the encounter complex was the limiting step. The parameter Kass 
described the association rate between α1PI and mNE and was therefore a good indicator 
for inhibition efficiency. Kass was 15 times worse for α1PI and tc-mNE, than α1PI and sc-
mNE. Of course tc-mNE was not as efficient in cleaving certain substrates. It was e.g. 
five times worse for the substrate Mca-GIATFCMLMPEQ-(Dnp)-rr. But this 15-fold 
functional impairment toward tc-mNE was comparable with the reduction of α1PI levels 
in homozygous Z allel carrier (10-15%). Individuals that carried the Z α1PI as well as the 
normal M α1PI had only a 25-40% decrease in the plasma levels of α1PI ((Zorzetto et al., 
2008). Under normal conditions these individuals were not at risk to develop emphysema. 
Only if an additional environmental factor added to it, these persons showed some decline 
in lung functions (Thun et al., 2012). If for example these persons developed a severe 
lung inflammatory disease, the high neutrophil infiltration of the lung would lead to 
increased levels of tc-mNE. I could clearly show that tc-mNE was less well inhibited by 
Z- α1PI as I could still detect tc-mNE activity, when sc-mNE was already inhibited. Since 
these high levels of tc-mNE were not properly inhibited, the risk for emphysema 
development would be tremendously increased. A high amount of tc-mNE alone might 
not lead to emphysema, but in combination with a trigger from the environment, e.g. 
smoking, infections, lung inflammation etc., it might worsen the prognosis.  
I was able to show that α1PI inhibition was impaired after NE has nicked itself. But as we 
already knew that the substrate specificity was diminished, the question as to whether tc-
mNE could still trigger emphysema remained to be answered. These studies have not 
been included in this thesis, but are currently performed in cooperation with Önder 
Yildirim. A first series of installation experiments showed that tc-mNE was still 
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pathogenic (data not shown). Tc-mNE was instilled into the respiratory tract of wt mice 
and after two months, emphysema development was observed. The data are still 
preliminary and have to be confirmed. 
Today, patients suffering from severe α1PI deficiency were already treated with α1PI 
infusions in some European countries. But individuals that were only heterozygous for 
the Z-allel were not regarded as severely α1PI deficient and were thus not treated by α1PI 
substitution therapy. Conversely, NE has already been recognized as a drug target for the 
prevention or treatment of lung disease. Consequently, many inhibitors have been 
developed to target NE in the past decade. None of these inhibitors were successful in 
clinical trial or approved by the authorities. It is still not known why these inhibitors 
failed. One possible reason might be the overlooked tc-mNE. In cooperation with Astra 
Zeneca I obtained one of these failed inhibitors and compared its efficiency against sc- 
and tc-mNE. The difference in their ability to inhibit sc- and tc-mNE was indeed greater 
than that of α1PI. Tc-mNE was insufficiently blocked by AZ111177 and therefore 
escaped these inhibitors. This may be the reason why this substance could not prevent 
further damage. 
Last but not least, as all experiments so far were done in vitro, the existence of tc-mNE in 
vivo had to be verified. In their native forms, the difference between sc- and tc-mNE was 
only one water molecule. Hence, western blot analysis under reducing conditions was the 
easiest way to detect tc-mNE. Since PMNs were the main source of NE, they were my 
first target. With the help of recombinant mNE, I was able to find an anti-hNE antibody 
that crossreacted with mNE and was suited for western blot analysis. The lysate of 
PR3/NE deficient PMNs was loaded as a negative control. I found two bands in wt PMN 
lysate that were clearly missing in PR3/NE deficient lysate. On these grounds I concluded 
that these bands were mNE. The upper band had the expected weight for sc-mNE, while 
the lower band is most likely tc-mNE. With this antibody tc-mNE had been successfully 
detected in a biological sample. The purification of mPMNs made use of a percoll 
gradient. PMNs were slightly activated by this procedure and so tc-mNE could be an 
artifact of the purification. That is why I repeated the experiments with whole bone 
marrow cells. The result was the same as with mPMNs (data not shown). In the case of 
hPMNs, I did not merely prove the existence of the tc-mNE form, but also demonstrated 
that it is active. By incubating the lysate with biotinylated AAPV-cmk inhibitor first, I 
have tagged all active hNE molecules. Subsequent immunoprecipitation with an anti-hNE 
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antibody had guaranteed the identification of hNE. I was able to detect active sc- and tc-
hNE in hPMNs. Further evidence for the natural occurrence of tc-NE could be found in 
the literature. Starkey et al. purified elastase from spleen using CM-cellulose and verified 
its identity with different substrates (Starkey and Barrett, 1976). SDS-PAGE of elastase 
revealed three distinct bands under reducing conditions at around 27, 15-20 and 10-13 
kDa. The sizes of these bands were estimated from the gel and fitted our data very well. 
In another study NE was purified from leukocytes. Additional to the purification with 
CM-cellulose a column with aprotinin, a serine protease inhibitor, was used (Baugh and 
Travis, 1976). Although the authors did not comment on this, a second band was visible 
after the purification with aprotinin. Since a marker was missing on the SDS gel, I was 
not able to judge whether the size fits tc-mNE. During in vitro studies with hNE, tc-hNE 
appeared after 168 hours (Padrines et al., 1989). Relatively low concentrations of only 
100 nM were used. This was probably the reason that the reaction took so long. In an 
attempt to elucidate the biosynthetic profile of hNE during PMN maturation, Garwicz et 
al. differentiated bone marrow progenitor cells and analyzed them at different days 
(Garwicz et al., 2005). After immunoprecipitation with an anti-hNE antibody, the samples 
were run on a SDS-PAGE. Two bands were visible on the SDS-PAGE. Clearly the 
nicking of NE has already been seen since 1976, but obviously ignored as unimportant or 
an artifact from purification. These findings as well pointed to the existence of tc-NE in 
vivo. 
Taken together our studies showed that tc-NE was able to escape inhibition. Bearing the 
pathophysiological role of NE in mind, this was especially important, as tc-NE was 
longer active and could cause damage for a longer period of time. Up to now tc-mNE was 
never considered as a separate target during the development of therapeutical inhibitors 
and therefore these inhibitors were not designed to inactivate the tc-NE sufficiently. In an 
attempt to find a suitable inhibitor, I mutated the RCL of α1PI. I replaced Met
358
 with 
Met, Thr and Cys, because the difference between sc-and tc-mNE was smaller when 
using substrates featuring these mutations (data not shown). All three α1PI variants were 
able to inhibit sc- and tc-mNE irreversible, but I did not determine yet whether these α1PI 
variants inhibit tc-mNE better.  
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5.3 Conclusion 
In conclusion, these studies demonstrated the beneficial and destructive effects of PR3 
and NE as pro-inflammatory actors. I could show that PR3 and NE process chemokines, 
thereby enhancing the chemotactic properties of the chemokines. The PMNs were 
attracted to the inflammatory site by a chemokine gradient. Once they arrived at the 
inflammatory site they released PR3 and NE. Because of the high inhibitor 
concentrations, PR3 and NE were probably only active in a small area surrounding the 
neutrophil (Campbell et al., 1999). In this small activity zone, PR3 and NE could convert 
the chemokines to their more active form. This in turn would steepen the gradient and 
accelerate the recruitment of other neutrophils.  
Fig 5.2: Impact of extracellular NE. PR3 and NE are only active in a small area around the 
neutrophil before they are inactivated by the high inhibitor concentrations in their surroundings. 
Chemokines that are in the action radius are converted to their more active form by PR3 and NE. 
This steepens the chemokine gradient and accelerates the neutrophil recruitment. The action 
radius of the tc-mNE (red) is larger than that of the sc-mNE (blue), because it is more slowly 
inhibited by α1PI. This protracted activity of tc-mNE also extends the time during which tc-mNE 
can generate damage. Small molecule inhibitors developed against NE, inhibited tc-NE only 
insufficiently. 
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On the one hand the pro-inflammatory quality of extracellular functions warranted a fast 
response towards intruders; on the other hand uncontrolled activity of NE would be 
harmful and could cause emphysema. In this work, I was able to show a mechanism, in 
which NE could escape inhibition by α1PI. NE cleaved itself at high concentration as 
found in phagolysosomes. The resulting tc-NE had a narrower substrate specificity, which 
in turn impaired inhibition by the natural inhibitor α1PI. The action radius of tc-NE was 
therefore larger than that of sc-NE. Small molecule inhibitors developed for therapeutic 
applications inhibited tc-NE insufficiently. 
Understanding the pro-inflammatory role of NE and PR3 is necessary for better 
intervention during disease. In chronic inflammation inhibition of NE might prove 
beneficial. The existence of tc-NE should be taken into account for the development of 
suitable inhibitors for both forms of NE. 
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7 Abbreviations 
α1PI  a1-protease inhibitor 
ABTS  2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
Abz 2-aminobenzoyl 
AMC 7-amino-4-methylcoumarin 
ANCA antineutrophil cytoplasmic autoantibodies  
ATP  adenosine-5'-triphosphate 
BCA bicinchoninic acid  
CG cathepsin G 
Ch cherry 
cmk chloromethyl ketone 
COPD chronic obstructive pulmonary disease  
CXCR2 C-X-C chemokine receptor type 2 
DNA deoxyribonucleic acid 
DPPI dipeptidyl peptidase I 
EBNA Epstein-Barr nuclear antigen  
ECM extracellular matrix 
EDDnp N-(2,4-dinitrophenyl)ethylenediamine  
EDTA  ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
FCS fetal calf serum 
Fret fluorescence resonance energy transfer 
GPA granulomatosis with polyangiitis  
HBSS  Hank's balanced salt solution 
HEK human embryonic kidney cells 
HRP  horseraddish peroxidase 
IC immune complex 
IL-8 interleukin-8 
Kass association constant 
kcat catalytical constant 
Ki inhibitor constant 
Ki(app) apparent inhibitor constant 
KM Michaelis-Menten concentration  
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ko knockout 
kobs observed constant 
LIX LPS-induced CXC ckemokine 
MIP-2 macrophage inflammatory protein 2 
MMP matrix metalloproteinase 
MNEI monocyte neutrophil elastase inhibitor  
NE  neutrophil elastase 
NPGB p-nitrophenyl p-guanidinobenzoate hydrochloride 
NSP  neutrophil serine protease 
PBMC   peripheral blood mononuclear cell 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PEI polyethylenimine  
PLS Papillon-Lefèvre sndrome 
PMA phorbol myristate acetate 
PMN polymorphonuclear neutrophilic granulocytes 
pNA p-nitroanilide 
PR3  proteinase 3 
PVDF polyvinylidene fluoride  
RCL reactive center loop 
ROS reactive oxgen species 
ROS reactive oxygen species 
RPMI Roswell Park Memorial Institute medium 
Ru ruby 
SBzl thiobenzyl ester 
sc single chain 
SDS  sodium dodecyl sulfate 
TAE  tris-acetate-EDTA 
tc two chain 
TNFα tumor necrosis factor α 
TPCK  L-1-tosylamide-2-phenylethyl chloromethyl ketone 
vmax maximum velocity  
wt wildtype 
Z a1PI  Z variant of a1PI   
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8 Appendix 
8.1 Vector map of pTT5 
 
OriP: EBV origin of replication  
pMB1 ori: bacterial origin of replication  
CMV: Cytomegalovirus promoter 
TPL: adenovirus tripartite leader 
SD: splice donor 
enh. MLP: enhanced major late promoter 
SA: splice acceptor 
pA: rabbit beta-globin polyadenylation site 
 
 
 
Appendix 
- 86 - 
 
8.2 Sequence of expressed proteins  
Grey: Signalpeptide 
Fat: His-tag 
Underlined: propeptide with enterokinase cleavage site 
8.2.1 pTT5_NGS_mNE(wt)_st.H6 
M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G  
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGG 
         ^10       ^20       ^30       ^40       ^50  
 S  T  G  S  R  M  H  R  N  G  S  H  V  D  D  D  D  
TTCCACTGGTAGCCGCATGCACCGCAACGGCAGCCACGTGGATGACGACG 
         ^60       ^70       ^80       ^90       ^100 
  K  I  V  G  G  R  P  A  R  P  H  A  W  P  F  M   
ACAAGATTGTTGGTGGCCGGCCGGCCCGGCCCCATGCTTGGCCCTTCATG 
         ^110      ^120      ^130      ^140      ^150  
A  S  L  Q  R  R  G  G  H  F  C  G  A  T  L  I  A   
GCATCCCTGCAGAGGCGTGGAGGTCATTTCTGTGGTGCCACCCTCATTGC 
         ^160      ^170      ^180      ^190      ^200 
 R  N  F  V  M  S  A  A  H  C  V  N  G  L  N  F  R 
CAGGAACTTCGTCATGTCAGCAGCCCACTGTGTGAACGGCCTAAATTTCC 
         ^210      ^220      ^230      ^240      ^250 
  S  V  Q  V  V  L  G  A  H  D  L  R  R  Q  E  R   
GGTCAGTGCAGGTAGTGCTGGGAGCCCATGACCTGCGGCGACAGGAGCGC 
         ^260      ^270      ^280      ^290      ^300  
T  R  Q  T  F  S  V  Q  R  I  F  E  N  G  F  D  P   
ACTCGACAGACCTTCTCTGTGCAGCGGATCTTCGAGAATGGCTTTGACCC 
         ^310      ^320      ^330      ^340      ^350 
 S  Q  L  L  N  D  I  V  I  I  Q  L  N  G  S  A  T 
ATCACAACTGCTGAACGACATTGTGATTATCCAGCTCAATGGCTCCGCTA 
         ^360      ^370      ^380      ^390      ^400 
  I  N  A  N  V  Q  V  A  Q  L  P  A  Q  G  Q  G   
CCATTAACGCCAACGTGCAGGTGGCCCAGCTGCCTGCCCAGGGCCAGGGC 
         ^410      ^420      ^430      ^440      ^450  
V  G  D  R  T  P  C  L  A  M  G  W  G  R  L  G  T  
GTGGGTGACAGAACTCCATGTCTGGCCATGGGCTGGGGCAGGTTGGGCAC 
         ^460      ^470      ^480      ^490      ^500 
 N  R  P  S  P  S  V  L  Q  E  L  N  V  T  V  V  T  
AAACAGACCATCACCCAGTGTGCTACAAGAGCTCAATGTGACAGTGGTGA 
         ^510      ^520      ^530      ^540      ^550    
  N  M  C  R  R  R  V  N  V  C  T  L  V  P  R  R   
CTAACATGTGCCGCCGTCGTGTGAACGTATGCACTCTGGTGCCACGTCGG 
         ^560      ^570      ^580      ^590      ^600 
 
Q  A  G  I  C  F  G  D  S  G  G  P  L  V  C  N  N   
CAGGCAGGCATCTGCTTCGGGGACTCTGGCGGACCCTTGGTCTGTAACAA 
         ^610      ^620      ^630      ^650      ^650           
 
 
Appendix 
- 87 - 
 
 L  V  Q  G  I  D  S  F  I  R  G  G  C  G  S  G  L  
CCTTGTCCAAGGCATTGACTCCTTCATCCGAGGAGGCTGTGGATCTGGAT 
         ^660      ^670      ^680      ^690      ^700  
  Y  P  D  A  F  A  P  V  A  E  F  A  D  W  I  N 
TGTACCCAGATGCCTTCGCCCCTGTGGCTGAGTTTGCAGATTGGATCAAT   
         ^710      ^720      ^730      ^740      ^750        
S  I  I  R  K  P  R  H  H  H  H  H  H   
TCCATTATTCGAAAGCCTAGGCATCATCACCATCACCAT   
         ^760      ^770      ^780         
8.2.2 pTT5_NGS_mNE-KG187/8_st.H6 
M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G  
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGG 
         ^10       ^20       ^30       ^40       ^50  
 S  T  G  S  R  M  H  R  N  G  S  H  V  D  D  D  D  
TTCCACTGGTAGCCGCATGCACCGCAACGGCAGCCACGTGGATGACGACG 
         ^60       ^70       ^80       ^90       ^100 
  K  I  V  G  G  R  P  A  R  P  H  A  W  P  F  M   
ACAAGATTGTTGGTGGCCGGCCGGCCCGGCCCCATGCTTGGCCCTTCATG 
         ^110      ^120      ^130      ^140      ^150  
A  S  L  Q  R  R  G  G  H  F  C  G  A  T  L  I  A   
GCATCCCTGCAGAGGCGTGGAGGTCATTTCTGTGGTGCCACCCTCATTGC 
         ^160      ^170      ^180      ^190      ^200 
 R  N  F  V  M  S  A  A  H  C  V  N  G  L  N  F  R 
CAGGAACTTCGTCATGTCAGCAGCCCACTGTGTGAACGGCCTAAATTTCC 
         ^210      ^220      ^230      ^240      ^250 
  S  V  Q  V  V  L  G  A  H  D  L  R  R  Q  E  R   
GGTCAGTGCAGGTAGTGCTGGGAGCCCATGACCTGCGGCGACAGGAGCGC 
         ^260      ^270      ^280      ^290      ^300  
T  R  Q  T  F  S  V  Q  R  I  F  E  N  G  F  D  P   
ACTCGACAGACCTTCTCTGTGCAGCGGATCTTCGAGAATGGCTTTGACCC 
         ^310      ^320      ^330      ^340      ^350 
 S  Q  L  L  N  D  I  V  I  I  Q  L  N  G  S  A  T 
ATCACAACTGCTGAACGACATTGTGATTATCCAGCTCAATGGCTCCGCTA 
         ^360      ^370      ^380      ^390      ^400 
  I  N  A  N  V  Q  V  A  Q  L  P  A  Q  G  Q  G   
CCATTAACGCCAACGTGCAGGTGGCCCAGCTGCCTGCCCAGGGCCAGGGC 
         ^410      ^420      ^430      ^440      ^450  
V  G  D  R  T  P  C  L  A  M  G  W  G  R  L  G  T  
GTGGGTGACAGAACTCCATGTCTGGCCATGGGCTGGGGCAGGTTGGGCAC 
         ^460      ^470      ^480      ^490      ^500 
 N  R  P  S  P  S  V  L  Q  E  L  N  V  T  V  V  T  
AAACAGACCATCACCCAGTGTGCTACAAGAGCTCAATGTGACAGTGGTGA 
         ^510      ^520      ^530      ^540      ^550    
  N  M  C  R  R  R  V  N  V  C  T  L  V  P  R  R   
CTAACATGTGCCGCCGTCGTGTGAACGTATGCACTCTGGTGCCACGTCGA 
         ^560      ^570      ^580      ^590      ^600 
K  G  G  I  C  F  G  D  S  G  G  P  L  V  C  N  N   
AAGGGTGGCATCTGCTTCGGGGACTCTGGCGGACCCTTGGTCTGTAACAA 
         ^610      ^620      ^630      ^650      ^650           
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 L  V  Q  G  I  D  S  F  I  R  G  G  C  G  S  G  L  
CCTTGTCCAAGGCATTGACTCCTTCATCCGAGGAGGCTGTGGATCTGGAT 
         ^660      ^670      ^680      ^690      ^700  
  Y  P  D  A  F  A  P  V  A  E  F  A  D  W  I  N 
TGTACCCAGATGCCTTCGCCCCTGTGGCTGAGTTTGCAGATTGGATCAAT   
         ^710      ^720      ^730      ^740      ^750        
S  I  I  R  K  P  R  H  H  H  H  H  H   
TCCATTATTCGAAAGCCTAGGCATCATCACCATCACCAT   
         ^760      ^770      ^780         
8.2.3 pTT5_ MIP-(5-73)_H6 
M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G  
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGG 
         ^10       ^20       ^30       ^40       ^50  
 S  T  G  S  E  L  R  C  Q  C  L  K  T  L  P  R  V  
TTCCACTGGTAGTGAACTGCGCTGTCAATGCCTGAAGACCCTGCCAAGGG  
         ^60       ^70       ^80       ^90       ^100 
  D  F  K  N  I  Q  S  L  S  V  T  P  P  G  P  H   
TTGACTTCAAGAACATCCAGAGCTTGAGTGTGACGCCCCCAGGACCCCAC 
         ^110      ^120      ^130      ^140      ^150    
C  A  Q  T  E  V  I  A  T  L  K  G  G  Q  K  V  C     
TGCGCCCAGACAGAAGTCATAGCCACTCTCAAGGGCGGTCAAAAAGTTTG 
         ^160      ^170      ^180      ^190      ^200 
 L  D  P  E  A  P  L  V  Q  K  I  I  Q  K  I  L  N    
CCTTGACCCTGAAGCCCCCCTGGTTCAGAAAATCATCCAAAAGATACTGA  
         ^210      ^220      ^230      ^240      ^250 
  K  G  K  A  N  T  G  H  H  H  H  H  H   
ACAAAGGCAAGGCTAACACCGGTCATCATCACCATCACCAT 
         ^260      ^270      ^280      ^290 
8.2.4 pTT5_EK_MIP-2(1-73)_H6 
M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G  
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGG 
         ^10       ^20       ^30       ^40       ^50  
S  T  G  D  G  S  L  Q  G  D  D  D  D  K  A  V  V   
TTCCACTGGTGACGGGTCCCTGCAGGGCGACGACGACGACAAGGCTGTTG 
         ^60       ^70       ^80       ^90       ^100 
  A  S  E  L  R  C  Q  C  L  K  T  L  P  R  V  D   
TGGCCAGTGAACTGCGCTGTCAATGCCTGAAGACCCTGCCAAGGGTTGAC 
         ^110      ^120      ^130      ^140      ^150    
F  K  N  I  Q  S  L  S  V  T  P  P  G  P  H  C  A   
TTCAAGAACATCCAGAGCTTGAGTGTGACGCCCCCAGGACCCCACTGCGC   
         ^160      ^170      ^180      ^190      ^200 
 Q  T  E  V  I  A  T  L  K  G  G  Q  K  V  C  L  D 
CCAGACAGAAGTCATAGCCACTCTCAAGGGCGGTCAAAAAGTTTGCCTTG 
         ^210      ^220      ^230      ^240      ^250 
  P  E  A  P  L  V  Q  K  I  I  Q  K  I  L  N  K   
ACCCTGAAGCCCCCCTGGTTCAGAAAATCATCCAAAAGATACTGAACAAA 
         ^260      ^270      ^280      ^290      ^300  
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G  K  A  N  T  G  H  H  H  H  H  H   
GGCAAGGCTAACACCGGTCATCATCACCATCACCAT   
         ^310      ^320      ^330      
8.2.5 pTT5_MIP-2(5-73)_Ruby_H6 
M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G   
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGG 
         ^10       ^20       ^30       ^40       ^50  
 S  T  G  S  E  L  R  C  Q  C  L  K  T  L  P  R  V 
TTCCACTGGTAGTGAACTGCGCTGTCAATGCCTGAAGACCCTGCCAAGGG 
         ^60       ^70       ^80       ^90       ^100    
  D  F  K  N  I  Q  S  L  S  V  T  P  P  G  P  H   
TTGACTTCAAGAACATCCAGAGCTTGAGTGTGACGCCCCCAGGACCCCAC 
         ^110      ^120      ^130      ^140      ^150  
C  A  Q  T  E  V  I  A  T  L  K  G  G  Q  K  V  C 
TGCGCCCAGACAGAAGTCATAGCCACTCTCAAGGGCGGTCAAAAAGTTTG  
         ^160      ^170      ^180      ^190      ^200       
 L  D  P  E  A  P  L  V  Q  K  I  I  Q  K  I  L  N 
CCTTGACCCTGAAGCCCCCCTGGTTCAGAAAATCATCCAAAAGATACTGA 
         ^210      ^220      ^230      ^240      ^250       
  K  G  K  A  N  T  G  S  G  G  G  E  D  N  S  L   
ACAAAGGCAAGGCTAACACCGGTTCTGGTGGCGGTGAGGATAACAGCCTG 
         ^260      ^270      ^280      ^290      ^300  
I  K  E  N  M  R  M  K  V  V  L  E  G  S  V  N  G   
ATCAAAGAAAACATGCGGATGAAGGTGGTGCTGGAAGGCAGCGTGAACGG   
         ^310      ^320      ^330      ^340      ^350 
 H  Q  F  K  C  T  G  E  G  E  G  N  P  Y  M  G  T 
CCACCAGTTCAAGTGCACCGGCGAGGGCGAGGGCAACCCCTACATGGGCA 
         ^360      ^370      ^380      ^390      ^400     
  Q  T  M  R  I  K  V  I  E  G  G  P  L  P  F  A   
CCCAGACCATGCGGATCAAAGTGATCGAGGGCGGACCTCTGCCCTTCGCC 
         ^410      ^420      ^430      ^440      ^450  
F  D  I  L  A  T  S  F  M  Y G  S  R  T  F  I  K   
TTCGACATCCTGGCCACATCCTTCATGTACGGCAGCCGGACCTTCATCAA   
         ^460      ^470      ^480     ^490      ^500    
 Y  P  K  G  I  P  D  F  F  K  Q  S  F  P  E  G  F  
GTACCCCAAGGGCATCCCCGATTTCTTCAAGCAGAGCTTCCCCGAGGGCT 
         ^510      ^520      ^530      ^540      ^550   
  T  W  E  R  V  T  R  Y  E  D  G  G  V  I  T  V     
TCACCTGGGAGAGAGTGACCAGATACGAGGACGGCGGCGTGATCACCGTG  
         ^560      ^570      ^580      ^590      ^600     
M  Q  D  T  S  L  E  D  G  C  L  V  Y  H  A  Q  V   
ATGCAGGACACCAGCCTGGAAGATGGCTGCCTGGTGTACCATGCCCAGGT 
         ^610      ^620      ^630      ^640      ^650 
 R  G  V  N  F  P  S  N  G  A  V  M  Q  K  K  T  K    
CAGGGGCGTGAATTTTCCCAGCAACGGCGCCGTGATGCAGAAGAAAACCA 
         ^660      ^670      ^680      ^690      ^700  
  G  W  E  P  N  T  E  M  M  Y  P  A  D  G  G  L   
AGGGCTGGGAGCCCAACACCGAGATGATGTACCCCGCTGACGGCGGACTG 
         ^710      ^720      ^730      ^740      ^750       
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R  G  Y  T  H  M  A  L  K  V  D  G  G  G  H  L  S  
AGAGGCTACACCCACATGGCCCTGAAGGTGGACGGCGGAGGGCACCTGAG 
         ^760      ^770      ^780      ^790      ^800         
 C  S  F  V  T  T  Y  R  S  K  K  T  V  G  N  I  K  
CTGCAGCTTCGTGACCACCTACCGATCCAAGAAAACCGTGGGCAACATCA 
         ^810      ^820      ^830      ^840      ^850  
  M  P  G  I  H  A  V  D  H  R  L  E  R  L  E  E   
AGATGCCCGGCATCCACGCCGTGGACCACCGGCTGGAAAGGCTGGAAGAG  
         ^860      ^870      ^880      ^890      ^900 
S  D  N  E  M  F  V  V  Q  R  E  H  A  V  A  K  F  
TCCGACAACGAGATGTTCGTGGTGCAGCGGGAGCACGCCGTGGCCAAGTT 
         ^910      ^920      ^930      ^940      ^950  
A  G  L  P  G  G  H  H  H  H  H  H    
CGCCGGCCTGCCTGGAGGGCACCATCACCATCACCAT  
         ^960      ^970      ^980       
8.2.6 pTT5_ Cherry_MIP-2(1-73)_H6 
M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G   
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGG 
         ^10       ^20       ^30       ^40       ^50  
 S  T  G  D  V  S  K  G  E  E  D  N  M  A  I  I  K   
TTCCACTGGTGACGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCA  
         ^60       ^70       ^80       ^90       ^100  
  E  F  M  R  F  K  V  H  M  E  G  S  V  N  G  H     
AGGAGTTCATGCGCTTCAAGGTGCACATGGAGGGCTCCGTGAACGGCCAC 
         ^110      ^120      ^130      ^140      ^150        
E  F  E  I  E  G  E  G  E  G  R  P  Y  E  G  T  Q   
GAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCA 
         ^160      ^170      ^180      ^190      ^200 
 T  A  K  L  K  V  T  K  G  G  P  L  P  F  A  W  D   
GACCGCCAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCCTGGG 
         ^210      ^220      ^230      ^240      ^250 
  I  L  S  P  Q  F  M  Y  G  S  K  A  Y  V  K  H     
ACATCCTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAGCAC 
         ^260      ^270      ^280      ^290      ^300 
P  A  D  I  P  D  Y  L  K  L  S  F  P  E  G  F  K    
CCCGCCGACATCCCCGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAA   
         ^310      ^320      ^330      ^340      ^350       
 W  E  R  V  M  N  F  E  D  G  G  V  V  T  V  T  Q 
GTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCC 
         ^360      ^370      ^380      ^390      ^400        
  D  S  S  L  Q  D  G  E  F  I  Y  K  V  K  L  R   
AGGACTCCTCCCTGCAGGACGGCGAGTTCATCTACAAGGTGAAGCTGCGC 
         ^410      ^420      ^430      ^440      ^450    
G  T  N  F  P  S  D  G  P  V  M  Q  K  K  T  M  G   
GGCACCAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACCATGGG     
         ^460      ^470      ^480      ^490      ^500       
 W  E  A  S  S  E  R  M  Y  P  E  D  G  A  L  K  G   
CTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCCTGAAGG 
         ^510      ^520      ^530      ^540      ^550   
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  E  I  K  Q  R  L  K  L  K  D  G  G  H  Y  D  A     
GCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCT 
         ^560      ^570      ^580      ^590      ^600             
E  V  K  T  T  Y  K  A  K  K  P  V  Q  L  P  G  A   
GAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGC 
         ^610      ^620      ^630      ^640      ^650           
 Y  N  V  N  I  K  L  D  I  T  S  H  N  E  D  Y  T   
CTACAACGTCAACATCAAGTTGGACATCACCTCCCACAACGAGGACTACA 
         ^660      ^670      ^680      ^690      ^700  
  I  V  E  Q  Y  E  R  A  E  G  R  H  S  T  G  G   
CCATCGTGGAACAGTACGAACGCGCCGAGGGCCGCCACTCCACCGGCGGC 
         ^710      ^720      ^730      ^740      ^750       
M  D  E  L  Y  K  S  G  G  G  G  V  P  G  S  T  G  
ATGGACGAGCTGTACAAGTCTGGTGGCGGTGGGGTACCAGGTTCCACTGG 
         ^760      ^770      ^780      ^790      ^800       
 A  V  V  A  S  E  L  R  C  Q  C  L  K  T  L  P  R  
TGCTGTTGTGGCCAGTGAACTGCGCTGTCAATGCCTGAAGACCCTGCCAA 
         ^810      ^820      ^830      ^840      ^850  
  V  D  F  K  N  I  Q  S  L  S  V  T  P  P  G  P   
GGGTTGACTTCAAGAACATCCAGAGCTTGAGTGTGACGCCCCCAGGACCC    
         ^860      ^870      ^880      ^890      ^900 
H  C  A  Q  T  E  V  I  A  T  L  K  G  G  Q  K  V   
CACTGCGCCCAGACAGAAGTCATAGCCACTCTCAAGGGCGGTCAAAAAGT 
         ^910      ^920      ^930      ^940      ^950 
 C  L  D  P  E  A  P  L  V  Q  K  I  I  Q  K  I  L   
TTGCCTTGACCCTGAAGCCCCCCTGGTTCAGAAAATCATCCAAAAGATAC   
         ^960      ^970      ^980      ^990      ^1000          
  N  K  G  K  A  N  T  G  H  H  H  H  H  H 
TGAACAAAGGCAAGGCTAACACCGGTCATCATCACCATCACCAT   
         ^1010     ^1020     ^1030      
8.2.7 pTT5_α1PI_342K 
M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G   
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGG 
         ^10       ^20       ^30       ^40       ^50  
 S  T  G  E  D  P  Q  G  D  A  A  Q  K  T  D  T  S   
TTCCACTGGTGAGGATCCCCAGGGAGATGCTGCCCAGAAGACAGATACAT      
         ^60       ^70       ^80       ^90       ^100       
  H  H  D  Q  D  H  P  T  F  N  K  I  T  P  N  L   
CCCACCATGATCAGGATCACCCAACCTTCAACAAGATCACCCCCAACCTG 
         ^110      ^120      ^130      ^140      ^150 
A  E  F  A  F  S  L  Y  R  Q  L  A  H  Q  S  N  S   
GCTGAGTTCGCCTTCAGCCTATACCGCCAGCTGGCACACCAGTCCAACAG   
         ^160      ^170      ^180      ^190      ^200            
 T  N  I  F  F  S  P  V  S  I  A  T  A  F  A  M  L   
CACCAATATCTTCTTCTCCCCAGTGAGCATCGCTACAGCCTTTGCAATGC 
         ^210      ^220      ^230      ^240      ^250       
  S  L  G  T  K  A  D  T  H  D  E  I  L  E  G  L   
TCTCCCTGGGGACCAAGGCTGACACTCACGATGAAATCCTGGAGGGCCTG 
         ^260      ^270      ^280      ^290      ^300  
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N  F  N  L  T  E  I  P  E  A  Q  I  H  E  G  F  Q 
AATTTCAACCTCACGGAGATTCCGGAGGCTCAGATCCATGAAGGCTTCCA      
         ^310      ^320      ^330      ^340      ^350       
 E  L  L  R  T  L  N  Q  P  D  S  Q  L  Q  L  T  T 
GGAACTCCTCCGTACCCTCAACCAGCCAGACAGCCAGCTCCAGCTGACCA 
         ^360      ^370      ^380      ^390      ^400        
  G  N  G  L  F  L  S  E  G  L  K  L  V  D  K  F   
CCGGCAATGGCCTGTTCCTCAGCGAGGGCCTGAAGCTAGTGGATAAGTTT 
         ^410      ^420      ^430      ^440      ^450  
L  E  D  V  K  K  L  Y  H  S  E  A  F  T  V  N  F   
TTGGAGGATGTTAAAAAGTTGTACCACTCAGAAGCCTTCACTGTCAACTT      
         ^460      ^470      ^480      ^490      ^500       
 G  D  T  E  E  A  K  K  Q  I  N  D  Y  V  E  K  G  
CGGGGACACCGAAGAGGCCAAGAAACAGATCAACGATTACGTGGAGAAGG 
         ^510      ^520      ^530      ^540      ^550   
  T  Q  G  K  I  V  D  L  V  K  E  L  D  R  D  T   
GTACTCAAGGGAAAATTGTGGATTTGGTCAAGGAGCTTGACAGAGACACA   
         ^560      ^570      ^580      ^590      ^600            
V  F  A  L  V  N  Y  I  F  F  K  G  K  W  E  R  P     
GTTTTTGCTCTGGTGAATTACATCTTCTTTAAAGGCAAATGGGAGAGACC 
         ^610      ^620      ^630      ^640      ^650       
 F  E  V  K  D  T  E  E  E  D  F  H  V  D  Q  V  T   
CTTTGAAGTCAAGGACACCGAGGAAGAGGACTTCCACGTGGACCAGGTGA 
         ^660      ^670      ^680      ^690      ^700  
  T  V  K  V  P  M  M  K  R  L  G  M  F  N  I  Q   
CCACCGTGAAGGTGCCTATGATGAAGCGTTTAGGCATGTTTAACATCCAG      
         ^710      ^720      ^730      ^740      ^750       
H  S  K  K  L  S  S  W  V  L  L  M  K  Y  L  G  N  
CACAGTAAGAAGCTGTCCAGCTGGGTGCTGCTGATGAAATACCTGGGCAA 
         ^760      ^770      ^780      ^790      ^800        
 A  T  A  I  F  F  L  P  D  E  G  K  L  Q  H  L  E 
TGCCACCGCCATCTTCTTCCTGCCTGATGAGGGGAAACTACAGCACCTGG 
         ^810      ^820      ^830      ^840      ^850 
  N  E  L  T  H  D  I  I  T  K  F  L  E  N  E  D 
AAAATGAACTCACCCACGATATCATCACCAAGTTCCTGGAAAATGAAGAC   
         ^860      ^870      ^880      ^890      ^900       
R  R  S  A  S  L  H  L  P  K  L  S  I  T  G  T  Y  
AGAAGGTCTGCCAGCTTACATTTACCCAAACTGTCCATTACTGGAACCTA 
         ^910      ^920      ^930      ^940      ^950   
 D  L  K  S  V  L  G  Q  L  G  I  T  K  V  F  S  N   
TGATCTGAAGAGCGTCCTGGGTCAACTGGGCATCACTAAGGTCTTCAGCA     
         ^960      ^970      ^980      ^990      ^1000  
  G  A  D  L  S  G  V  T  E  E  A  P  L  K  L  S     
ATGGGGCTGACCTCTCCGGGGTCACAGAGGAGGCACCCCTGAAGCTCTCC 
         ^1010     ^1020     ^1030     ^1040     ^1050      
K  A  V  H  K  A  V  L  T  I  D  K  K  G  T  E  A   
AAGGCCGTGCATAAGGCTGTGCTGACCATCGACAAGAAAGGGACTGAAGC 
         ^1060     ^1070     ^1080     ^1090     ^1100      
 A  G  A  M  F  L  E  A  I  P  M  S  I  P  P  E  V   
TGCTGGGGCCATGTTCCTCGAGGCCATACCCATGAGTATACCCCCCGAGG    
         ^1110     ^1120     ^1130     ^1140     ^1150      
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  K  F  N  K  P  F  V  F  L  M  I  E  Q  N  T  K   
TCAAGTTCAACAAACCCTTTGTCTTCTTAATGATTGAACAAAATACCAAG 
         ^1160     ^1170     ^1180     ^1190       
S  P  L  F  M  G  K  V  V  N  P  T  Q  K  T  G  H   
TCTCCCCTCTTCATGGGAAAAGTGGTGAATCCCACCCAAAAAACCGGTCA   
         ^1210     ^1220     ^1230     ^1240     ^1250  
 H  H  H  H  H   
TCATCACCATCACCAT 
         ^1260    
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8.3 List of constructs 
name of construct vector insert method oligonucleotide 
restriction 
enzymes 
pTT5_S_mNE(wt)_H6 pTT5 pcDNA5/FRT_S_mNE_H6 Subklonierung - NheI + NaeI/PmeI 
pTT5_NGS_mNE(wt)_H6 pTT5_S_mNE(wt)_H6  Oligoduplex DJ3385/DJ3386 PmlI + KpnI 
pTT5_NGS_mNE-KG188/9_H6 pTT5_NGS_mNE(wt)_H6  Oligoduplex DJ3395/3396 AlfI 
pTT5_NGS_mNE(wt)_st.H6 pTT5_S_mNE(wt)_H6  Oligoduplex DJ3397/DJ3398 BstBI + BamHI 
pTT5_NGS_mNE-
KG187/8_st.H6 
pTT5_NGS_mNE-
KG188/9_H6 
 Oligoduplex DJ3397/DJ3398 BstBI + BamHI 
pCDNA5/FRT_S_mNE-
KG187/8_w/o-glyc_H6 
pcDNA5/FRT_S_mNE_H6 pTT5_S_mNE(wt)_H6 PCR DJ3469/DJ3470 AleI +BstXI/EagI 
pTT5_NGS_mNE(wt)_w/o-
glyc_st.H6 
pTT5 pCDNA5/FRT_S_mNE(wt)_
w/o-glyc_H6 
Subklonierung  EagI + BmgBI 
pTT5_NGS_mNE(A195)_st.H6 pTT5_NGS_mNE(wt)_st.H6  Oligoduplexe DJ3532/DJ3533 AlfI 
pTT5_ MIP-(5-73)_H6 pTT5 cDNA PCR DJ3310/DJ3311 AgeI + KpnI 
pTT5_MIP-2(1-73)_H6 pTT5 cDNA PCR DJ3309/DJ3310 AgeI + KpnI 
pTT5_EK_MIP-2(1-73) pTT5 cDNA PCR DJ3354/DJ3340 Age + SfbI 
pTT5_EK_MIP-2(1-73)_H6 pTT5 pTT5_EK_MIP-2(73) PCR DJ3310/DJ3376 AgeI + KpnI 
pTT5_MIP-2(5-73)_Ruby_H6 pTT5 cDNA PCR DJ3374/DJ3375 AgeI + BamHI 
pTT5_ Cherry_MIP-2(1-73)_H6 pTT5_MIP-2(73) cDNA PCR DJ3341/DJ3342 KpnI 
pTT5_α1PI_wt pTT5 pUC57_hsa1pi Subklonierung  KpnI + AgeI 
pTT5_α1PI_M358T pTT5_α1PI_wt  Oligoduplex DJ3553/ DJ3554 AbsI + AccI 
pTT5_α1PI_E342K pTT5_α1PI_wt pUC57_hsa1pi PCR DJ3557/ DJ3558 EcoRV + AbsI 
pTT5_MNEI pTT5     
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Presentations at international conferences 
02/2013 Oral presentation on “Decreased inhibitory capacity of natural α1-
antitrypsin towards an autoprocessed two-chain form of neutrophil 
elastase”. 26th International Winter School on Proteinases and Their 
Inhibitors. Italy. 
06/2012 Poster presentation of “Autoprocessing of neutrophil elastase near its 
active site counteracts alpha-1-antitrypsin inhibition” Gordon 
Research Conference: Proteolytic Enzymes and Their Inhibitors. Italy, 
2010. 
02/2011 Oral presentation on “Instability and self-digestion of neutrophil 
elastase”. 26th International Winter School on Proteinases and Their 
Inhibitors. Italy. 
02/2010 Oral presentation on “Chemokines as targets of neutrophil serine 
proteases”. 26th International Winter School on Proteinases and Their 
Inhibitors. Italy.  
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